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Angiotensin converting enzyme (ACE) is a key regulator of blood pressure and comprised of 
two homologous domains (N- and C-domain), both of which are glycosylated. N-linked 
glycosylation is important for the processing, expression and stability of ACE, but it interferes 
with protein crystallization. Previously, the N-glycan site occupancy required for the 
expression and stability of the individual domains of ACE was determined using minimally 
glycosylated (MG) N- and C-domain isoforms. However the role of glycosylation in the 
structure and function of the full-length somatic ACE (sACE) has remained elusive. A novel 
MG-sACE mutant, comprised of previously characterized MG N- and C-domains was 
generated. Unfortunately, the protein was susceptible to limited proteolysis in the inter-
domain linker region, suggesting that key glycans might shield the linker region from 
proteolysis. Furthermore, a loss in expression of MG-sACE was observed. These 
observations prompted the investigation of the effect of N-glycosylation on protection from 
inter-domain linker proteolysis, expression and overall stability of sACE. These aims were 
addressed by generating a panel of sACE glycosylation mutants. The minimal glycosylation 
requirements for an MG-sACE mutant that was least susceptible to inter-domain linker 
proteolysis was found to be six intact glycosylation sites (N25, N45, N416, N666 and N685). 
Furthermore, we determined that N-glycans on the C-domain confer most of sACE’s 
resistance to proteolysis. Surprisingly, the presence of glycosylation site 2 (N25) resulted in 
a sharp increase in MG-sACE linker proteolysis, which was blunted significantly by the 
presence of site 6 (N131) and site 12 (N666). Additionally, while site 2 (N25) had no effect 
on MG-sACE expression, site 6 (N131) was found to be crucial for sACE expression and the 
thermal stability of sACE. Furthermore, site 6 (N131) was able to rescue the thermal stability 
of the least stable MG-sACE (from 9% to 20% remaining enzymatic activity). A combination 
of N-glycans N45, N131, N480, N666 and N685 produced an MG-sACE mutant with 
substantially reduced inter-domain linker proteolysis. We also determined that MG-sACE 




Finally, inter-domain linker proteolysis was found to occur intracellularly, evidenced by the 
secretion of the N-domain to the extracellular milieu, intracellular retention and degradation 
of both the N- and C-domains, and exportation of MG-sACE to the cell surface. This work 
enhances our understanding of the glycosylation requirements of somatic ACE and provides 
a solid foundation for obtaining a stable, high expressing MG-sACE mutant that has the 
potential to generate the first full-length sACE crystal structure.
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Chapter 1: Introduction 
1.1 ANGIOTENSIN CONVERTING ENZYME (ACE)  
Angiotensin-converting enzyme (ACE), also known as peptidyl-dipeptidase A, is a zinc 
metalloprotease grouped under the M2 family of the MA clan sharing a single evolutionary 
ancestor (Acharya et al., 2003; Coates, 2003). ACE was first discovered in mid-1950s by 
Skeggs and colleagues (Skeggs, 1993; Skeggs, Kahn, et al., 1956). This discovery arose 
from research that was being conducted on Renin, the first enzyme in the Renin angiotensin 
aldosterone system (RAAS) (see section 1.1.3). Here, Skeggs was able to purify two 
products, now known as angiotensin I (AngI) (hypertensin I) and angiotensin II (AngII) 
(hypertensin II) (Skeggs et al., 1954). It was soon discovered that AngI was a product of 
Renin and AngII was a product of a hypertensin-converting enzyme (Skeggs, Kahn, et al., 
1956; Skeggs et al., 1954), now known as ACE. Additional investigations resulted in a 
significant body of information on ACE, which facilitated a better understanding of the RAAS 
(Bumpus et al., 1957; Elliott et al., 1956; Rittel, 1957; Skeggs, Lentz, et al., 1956). We now 
know that ACE displays its diversity by playing important roles in several physiological 
processes, the most notable of which are the kallikrein-kinin system (KKS) (E. G. Erdos, 
2006; Yang et al., 1967) and the abovementioned RAAS (Bernstein et al., 2013; Campbell, 
2001; Fyhrquist et al., 2008). 
1.1.1 The ACE Gene 
The human ACE gene is located on the chromosomal locus 17q23, spanning 21 kilobases 
with 26 exons (Hakkarainen et al., 2012). ACE has two isoforms, somatic ACE (sACE), 
expressed universally in somatic tissues and testis ACE (tACE), expressed only in the male 
spermatozoa (Tigerstedt et al., 2009; Tigerstedt et al., 2010). These isoforms are the result 
of two distinct promoter regions in the 4024 nucleotide ACE gene, the first of which is 




Figure 1.1: Diagrammatic representation of the ACE gene and protein structure. sACE is composed of two domains which 
are expressed off the somatic promoter region (sACE pro) upstream of the complete gene. tACE is the genetic and peptide 
equivalent of the C-domain of sACE and a result of an internal testis ACE promoter (tACE pro). Protein sequences that show 
high sequence homology are indicated with vertical stripes, active site(s) are indicated with diagonal stripes, in close proximity 
to the zinc binding site. N-terminal signalling peptides are indicated in grey and C-terminal hydrophobic membrane anchor 
region is indicated with horizontal stripes (Adapted from Coates et al. 2003.). 
kilobase sACE mRNA, and the second is located in intron 12, initiating the transcription of a 
3.0-kilobase tACE  mRNA (Langford et al., 1991; Soubrier et al., 1988) (Figure 1.1).  
 
1.1.2 Structural properties  
Human sACE cloning was first completed in 1988 by Soubrier and colleagues. It was found 
that immature human sACE is synthesized as a 1306 amino acid chain, with a 29 amino acid 
containing signal peptide (Soubrier et al., 1988). The resultant mature enzyme is 146.6 kDA 
(predicted mass) and contains 1277 amino acids (Soubrier et al., 1988). sACE is a highly 
conserved enzyme between eukaryotes, sharing protein sequence homology of 84.37% with 
porcine, 83.35% with rat, 82.21% with mouse, 83.80% with chimpanzee, and 84.49% with 
bovine sACE homologues (Figure 1.2). The sACE isoform is comprised of two homologous 
domains termed the N- and the C- domain, joined by a short inter-domain linker region. 
These domains display 60% amino acid sequence homology and both are catalytically active 
with a HEMGH, zinc dependent active site motif. However, they have different substrate, 
inhibitor, functional and chloride ion dependency profiles (Acharya et al., 2003; Bernstein et 




with a short 36-amino acid peptide located at the N-terminus of the isoform (Acharya et al., 
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Figure 1.2 : Multiple sequence alignment of human, porcine, rat, mouse, chimp and bovine sACE’s. Navy blue 






1.1.1.2 N- and C-domain structures 
The first N- and C-domain structures solved were obtained via the expression of the 
constructs in the presence of an α-glucosidase-I inhibitor (N-butyldeoxy-nojirimycin (NB-
DNJ)), which prevents the post-translational addition of complex oligosaccharides, limiting it 
only to the N-glycan backbone and thus allowing sufficient processing of the protein (Corradi 
et al., 2006; Natesh et al., 2003) (see section 1.2.2). As successful as this approach was, the 
potential loss of protein expression and the elevated cost prompted the development of a 
cheaper and more reliable method of generating reproducibly crystallisable sACE constructs. 
To this end, minimally glycosylated individual domains (N-domain with glycosylation sites 3 
(Asn45), 8 (Asn416) and 9 (Asn480) (Anthony et al., 2010), and C-domain with glycosylation 
sites 11 (Asn648) and 13 (Asn685) (Gordon et al., 2003)) were generated via site directed 
mutagenesis (SDM) and subsequently resulted in the high resolution crystal structures 
(Figure 1.3).  
 
Figure 1.3: Three-dimensional X-ray crystal structures of the N-domain (blue) and the C-domain (green) (PDB 
accession numbers: 2C6F and 1O86, respectively). Potential N-glycosylation sites are indicated in red with their respective 
residue numbers. The inter-domain linker region is indicated in black (circle). N-glycans at positions Asn45, Asn416, Asn480, 





To date, a number of individual domain structures have been co-crystallized with synthetic 
and natural inhibitors of sACE (Akif, Masuyer, et al., 2011; Akif, Schwager, et al., 2011; 
Douglas et al., 2014; Masuyer et al., 2012; Watermeyer et al., 2010). 
 
1.1.1.3 Full-length sACE structural model  
Although the high resolution 3D crystal structure of the full-length sACE has been elusive, 
Chen et.al have successfully solved a 3D electron microscope structure of porcine ACE 
fitted to the above mentioned human N- and C-domains (Chen et al., 2010). As previously 
mentioned, human and porcine sACE share a high level of protein sequence homology, 
making the predicted reconstruction of sACE fairly reliable. In this study, the low resolution 
model of 2.3 nm was sufficient to show the spatial arrangement of the domains, including the 
inter-domain linker region (Chen et al., 2010). Interestingly, the model also highlighted the 
proposed hinge-movement important during substrate binding (Towler et al., 2004). This was 
particularly evident in the C-domain displaying it in its “open” conformation.  Furthermore, the 
active sites of both domains were distinct in volume, and the domains were orientated at an 
incline of about 60°, separated by the approximately 2.0-2.5 nm long inter-domain linker. 
These data combined show sACE beginning with the N-domain residue Leu1 and spanning 
a further 600 residues to the beginning of the inter-domain linker region at Pro602 (Acharya 






The N-domain active site motif, HEMGH spans from 361-365, with the zinc coordinating 
residues His361 and His365, and the downstream Glu389. The inter-domain linker region 
spans a total of 15 amino acid residues, inclusive of the tripeptide, Leu613-Val614-Thr615, 
which is absent in the crystal structures of the individual domains. The C-domain begins at 
Glu617 and ends at Pro1193 (Corradi et al., 2006; Gordon et al., 2003; Natesh et al., 2003). 
Figure 1.4: Three-dimensional reconstructed model of human sACE. The model was reconstructed 
from the electron microscopic structure (net) of porcine ACE combined with the individual X-ray crystal 
structures of human sACE (Chen, Lunsdorf et al. 2010, Danilov, Gordon et al. 2011). The N-domain is 
indicated in blue spanning from Leu1 to Pro601. The inter-domain linker region is indicated in black 
spanning from Pro602 to Asp616. The C-domain is indicated in green, spanning from Glu617 to Pro1193. 
The stalk region spans from Gln1194 to Arg1227. The transmembrane region spans from Val1228 to 
Ser1248. The cytoplasmic tail spans from Gln1249 to Ser1277. The ACE sheddase is also indicated on 




This region includes the HEMGH (959-963) active site motif and the zinc coordinating 
residue Glu987. It is then followed by the 34-amino acid stalk region (Gln1194-Arg1227) 
which contains the Arg1203 sheddase cleavage site (Danilov et al., 2011; Woodman et al., 
2005). A hydrophobic transmembrane region extends from Val1228 to Ser1248, followed by 
the cytoplasmic tail (Gln1249-Ser1277).  
1.1.3 Biological roles of sACE 
ACE’s two domain structure make it versatile in the hydrolysis of diverse peptides. It’s native 
structure and cellular location also allows for involvement in other important physiological 
roles. ACE is a zinc dependent (Wei et al., 1991) dipeptidyl carboxypeptidase (Lentz et al., 
1956; Soffer et al., 1978) and an endopeptidase (Jaspard et al., 1993). 
1.1.3.1 Traditional roles 
The most notable role of ACE has been in blood pressure regulation through the RAAS and 
the KKS. Briefly, the aspartic protease, Renin, catalyses the cleavage of angiotensinogen to 
the decapeptide AngI. ACE then converts of AngI to the vasoconstrictive octapeptide AngII 
through its dipeptidyl peptidase function, while simultaneously converting the vasodilator 
bradykinin (BK) to its inactive fragment BK1-7 (Figure 1.5). 
Figure 1.5: Overview of the central role of ACE in blood pressure regulation. AngI – Angiotensin I, AngII – Angiotensin II, 
AT1 – Angiotensin II type I receptor, ADH- Antidiuretic Hormone, BK1-9 – Bradykinin (active), BK1-7 – Bradykinin (inactive) and B2 




It is now well known that the primary in vivo site of AngI hydrolysis is the C-domain, while 
both domains hydrolyse BK equally (Bernstein et al., 2011; Fuchs et al., 2004; Fuchs et al., 
2008; Junot et al., 2001). Current non-domain selective ACE inhibitors result in BK 
associated side effects such as angioedema and persistent cough that hamper the efficient 
treatment of hypertension (Acharya et al., 2003; Bernstein et al., 2011; Ehlers et al., 2013; 
Kroger et al., 2009). As previously mentioned, tACE is solely synthesized in the testis and 
has been shown to be crucial for male fertility (Esther et al., 1997; Hagaman et al., 1998). 
Furthermore, recent evidence has revealed that ACE is essential for the production of fertile 
spermatozoa through the removal of the GPI-anchored protein TEX10 (Y. Fujihara et al., 
2013). The N-domain of sACE is known to hydrolyse a variety of substrates. The most 
notable of which is the hydrolysis of the naturally occurring anti-fibrotic peptide, N-acetyl-
seryl-aspartyl-lysyl-proline (Ac-SDKP) (E. G. Erdos et al., 1967; Li et al., 2010; Skeggs, 
1993). Gonadotropin-releasing hormone (GnRH), a mediator of the release of follicle 
stimulating hormone, has been shown to be inactivated by the activity of the N-domain (G. 
Erdos et al., 2006; Papakyriakou et al., 2007; Taaseh et al., 2011). One striking function of 
the N-domain is the hydrolysis of the Alzheimer’s disease related amyloid-β peptide1-42 
(aβ42) to the less detrimental aβ40 (Zou et al., 2009; Zou et al., 2007). 
1.1.3.2 Non-traditional roles 
A number of studies have recently focused on the non-traditional roles of sACE. A detailed 
review on this topic is beyond the scope of this thesis but it is covered elegantly by 
(Gonzalez-Villalobos et al., 2013) and (Bernstein et al., 2013). Briefly, sACE is involved in 
the in cytokine production evidenced by the reduced levels of TNFα in ACE-null mice (Ong 
et al., 2012). sACE has also been implicated as a signalling molecule in a number of studies 
(Fleming, 2006; Guimaraes et al., 2011; Kohlstedt et al., 2004; Kohlstedt et al., 2009; 
Kohlstedt et al., 2002; Lucero et al., 2010). Another interesting role lies within the immune 
response where sACE is believed to aid in antigen presentation to the major 




Z. Shen et al., 2008; Sherman et al., 1992). sACE has also been shown to be an important 
factor in developing hematopoietic tissues of the human embryo and fetus (Jokubaitis et al., 
2008; Sinka et al., 2012; Zambidis et al., 2008). Finally myelopoiesis is thought to be 
regulated by sACE through the hydrolysis of its substrate, substance P (SP), and 
angiotensin receptor 1 (AT1) signalling, by the upregulation of CCAAT/enhancer-binding 
protein α, an important stimulator of myelopoiesis (Lin et al., 2011). 
1.1.4 ACE inhibitors 
ACE inhibition has been used for decades to treat hypertension, with several ACE inhibitors 
being commercially available, the most widely used being lisinopril. Classic ACE inhibitors 
are non-selective for the domains of ACE. These have been associated with side effects 
such as angioedema, persistent cough, loss of taste and skin rash (Bicket, 2002; Coulter et 
al., 1987; Slater et al., 1988; Speirs et al., 1998). The last two are a result of sulfhydryl group 
containing inhibitors such as captopril, leading to the rapid avoidance of the use of these 
inhibitors (Acharya et al., 2003; Adam et al., 2002; Dickstein et al., 2002). Angioedema is an 
uncommon side effect, affecting up to 0.5% of patients, while persistent cough affects up to 
20% of patients (Acharya et al., 2003; Adam et al., 2002; Dickstein et al., 2002). These 
adverse side effects have been associated with the increased levels of BK, due to the non-
selective inhibition of both the N- and C-domain (Acharya et al., 2003; Adam et al., 2002; 
Dickstein et al., 2002). This has set the platform to develop ACE inhibitors that will 
selectively inhibit either the N- or the C-domain individually. The C-domain has been shown 
to be the major cleavage site of AngI, therefore, selective C-domain inhibition will allow the 
N-domain to continue BK hydrolysis while conversion of AngI to AngII is inhibited, reducing 
hypertension. While selective N-domain inhibition will result in the reduced hydrolysis of 
AcSDKP (see section 1.1.3.1) which can be useful in combination therapy with bleomycin, 
reducing lung fibrotic effects usually observed with this anti-cancer treatment while 
maintaining normotensive conditions mediated by the activity of the C-domain (Bernstein et 




and RXPA380 (Georgiadis et al., 2004) respectively, have been developed. However, 
RXP407 is not a good candidate due to its low bioavailability. Furthermore, new N- (Douglas 
et al., 2014) and C-domain (Masuyer et al., 2012) selective inhibitors are currently being 
studied.  
1.2 PROTEIN GLYCOSYLATION 
Protein glycosylation is one of the most important post-translational modifications in 
eukaryotes and has been shown to be involved in a number of key cellular processes such 
as protein solubility, folding, stability and localization, to name a few (Csala et al., 2012; A. 
Helenius et al., 2004; Yan et al., 2005). Almost 50% of all eukaryotic proteins are predicted 
to be glycosylated and 90% of those are N-linked (Apweiler et al., 1999).  
1.2.1 O-linked glycosylation 
This process of O-linked glycosylation is primarily initiated in the Golgi apparatus and 
secondarily in the endoplasmic reticulum (ER), resulting in the addition of N-acetyl-
galactosamine (GlcNAc) to serine or threonine residue through the action of 
glycosyltransferases, using an activated membrane anchored polyisoprenoid lipid (dolichol 
(Dol)) bound monosaccharaides as substrates (An et al., 2011; Gill et al., 2010; Mitra et al., 
2006). O-linked glycans are often found at serine/threonine rich areas with no particular 









1.2.2 N-linked glycosylation 
N-linked glycans are found on the surface of many proteins forming bulkier side chains and 
occurring much more frequently than O-linked glycans (An et al., 2011; Apweiler et al., 1999; 
Csala et al., 2012; A. Helenius et al., 2004; Imperiali et al., 1999; Mitra et al., 2006). They 
occur only at the asparagine residue found in the conserved sequence, Asn-Xxx-Thr/Ser 
(Xxx being any amino acid except proline) (An et al., 2011; Imperiali et al., 1999). Three 
types of N-glycans exist: high mannose, complex and hybrid (Figure 1.6). 
 
 
High mannose glycans are composed of the trimannosyl pentasaccharide (GlcNac and Tri-
Man) backbone bound to a variety of mannose residues (An et al., 2011). Complex glycans 
include the typical backbone bound to varying residues such as galactose (Gal) or sialic acid 
(NeuAc) as well as additional GlcNAc residues, responsible for the complex nature (Figure 
1.6) (An et al., 2011). The glycan composition of these can be altered considerably due to 
the presence of a wide range of glycosyltransferases synthesized simultaneously with the 
Figure 1.6: Three categories of N-linked glycans including the trimannosyl pentasaccharide core backbone. (Adapted 





complex glycans. Hybrid glycans include the components of high mannose and complex 
glycans bound to the typical pentasaccharide backbone (Figure 1.6). However these glycans 
can have additional GlcNac, Gal, NeuAc and fucose residues added during synthesis (An et 
al., 2011). N-linked glycans are synthesized partially in the cytosol and then in the ER by an 
oligosaccharyltransferase using dolichyl pyrophosphate (Dol-PP) bound nucleotide sugars 
as substrates to add residues to the glycan backbone (Jones et al., 2005). When all residues 
of the glycan have been added, the intermediate Man5GlcNAc2-Dol-PP, is flipped into ER 
lumen by flippases that are very well characterized, but yet to be identified (J. Helenius et al., 
2002) (Figure 1.7).  
Figure 1.7: Protein glycosylation in the endoplasmic reticulum. The core glycan is partially assembled on dolichol 
pyrophosphate in the cytosol. The Man5GlcNAc2-PP-Dol glycan intermediate is “flipped” across the membrane by an unidentified 
flippase. Addition of glucose and mannose is catalysed by glycosyltranferases using Dol-P-Man and Dol-P-Glc as substrates. 
Finally, oligosaccharyltransferase adds the complete glycan en bloc to the asparagine residue in the glycosylation site. Dol = 
dolichol; ER = endoplasmic reticulum; FLIP = flippase; GT = glucosyltransferase; NDP = nucleoside diphosphate; NMP = 
nucleoside monophosphate; NST = nucleotide sugar transporter; OST = oligosaccharyltransferase; PT = phosphate transporter. 





Synthesis continues in the ER by addition of sugars from Dol-PP linked monosaccharaides, 
which are synthesized in the cytosol and subsequently flipped into the ER lumen. The 
complete N-glycan is then coupled to the nitrogen on the side chain of Asn (in the previously 
mentioned motif) in the growing nascent polypeptide through an N-glycosidic bond and 
promptly undergoes refinement through elongation by glycosyltransferases and trimming by 
glycosidases (A. Helenius et al., 2004; Jones et al., 2005). This continues until glycopeptide 
chains can be recognized by the calnexin-calreticulin cycle (see section 1.2.3.1).  
1.2.3 Glycosylation and protein folding 
N-Glycan mediated protein folding occurs co-translocationally when the polypeptide enters 
the Sec61 translocon channel in the ER lumen (Cheng, 2010; Osborne et al., 2005), 
proceeding until complete dissociation of the peptide chain from the ribosome (Bergman et 
al., 1979; Daniels et al., 2003; A. Helenius et al., 2004). The oligomeric nature of unfolded 
proteins requires conversion to their final folded state in this manner. Additionally, a number 
of proteins require the presence of glycans to allow efficient secretion, highlighting the 
importance of N-glycans in protein folding (Csala et al., 2012; A. Helenius et al., 2004). 
Some polypeptide chains that are synthesized lacking the presence of N-linked glycans fail 
to reach the oligomeric state and do not undergo the complex folding procedure. These are 
retained in the ER where they are degraded, preventing the accumulation of misfolded and 
potentially inactive proteins (Csala et al., 2012; A. Helenius et al., 2004). Clearly, protein 
folding is one of the most crucial roles of N-linked glycosylation in eukaryotes. In addition, N-
linked glycosylation is known to affect protein folding both indirectly and directly. 
1.2.3.1 Indirect effects of N-glycosylation on protein folding 
The calnexin-calreticulin cycle is a molecular chaperone system that mediates complex N-
linked glycosylation associated protein folding in the ER (Frenkel et al., 2004; A. Helenius et 
al., 2004; Lederkremer et al., 2005; Trombetta et al., 1998). The system comprises of 
calnexin, an ER-bound type I trans-membrane and the soluble calreticulin, found in the ER 




nascent polypeptide in the ER. This attachment occurs through monoglucosylated N-linked 
oligosaccharides on the polypeptide chain, found in the proline-rich area called the P-domain 
(Trombetta et al., 1998). This monoglycosylation is a result of glucosidase I and II activity, 
which catalyse the stepwise removal of two outermost glucose residues, while 
glucosyltransferase promptly reglucosylates incompletely folded proteins cyclically until the 
correct protein conformation is reached (Figure 1.8) (Trombetta et al., 1998). 
Calnexin and calreticulin present the monoglucosylated protein intermediate to ER protein 
57 (ERp57), a thioldisulfide oxidoreductase responsible for assisting the formation of 
disulphide bridges to the protein being folded (Frenkel et al., 2004; A. Helenius et al., 2004; 
Trombetta et al., 1998). Properly folded proteins can no longer bind to either calnexin or 
Figure 1.8: Calnexin-calreticulin mediated protein folding in the endoplasmic reticulum. Following addition of the core 
glycan to the polypeptide chain, the three outermost glucose residues (n) are removed by glucosidase I, followed by removal of 
the middle (m) glucose by glucosidase II, generating monoglucosylated glycans. These then bind to calnexin (CNX) and 
calreticulin (CRT) for presentation to ERp57. Glucosidase II removes the remaining glucose, leading to dissociation of the 
polypeptide-calnexin/calreticulin complex. The protein intermediate then goes through one of three steps; If properly folded, it 
leaves the ER via mannose lectins such as ERGIC-53, VIP36 and VIPL; If it is not completely folded, UDP-Glc (glycoprotein 
glucosyltransferase) uses UDP-glucose transported by a UDP-glucose/UMP exchanger  to reglucosylate the incompletely 
folded protein; finally, misfolded proteins undergo ER-associated degradation (ERAD) by recognition of a putative lectin 
(EDEM) that have lost a mannose residue through the action of ER mannosidase I.  Triangles –  Glucose, VIP36 –  vesicular 
integral protein 36, VIPL –  VIP36-like protein, ERAD –  ER-associated protein degradation, ERGIC-53 –  ER-Golgi 





calreticulin and are thus released from the ER via ER-Golgi intermediate compartment 53 
(ERGIC-53), vesicular integral protein 36 (VIP36) and VIP36-like protein (VIPL) (A. Helenius 
et al., 2004; Trombetta et al., 1998; Yamaguchi et al., 2007). ERGIC-53 is mainly 
responsible for the export of secretory and lysosomal proteins from the ER to the Golgi. 
VIP36 is more specific for proteins containing β-1,2 mannoses and it is proposed that it 
mediates forward transport of proteins for secretion (A. Helenius et al., 2004). VIPL is 
specific for high mannose sugars and is also responsible for the glucosylation of the α-1,2 
mannoses which it binds (Yamaguchi et al., 2007). Incompletely folded protein intermediates 
are recognized and reglucosylated only by UDP-Glc-glycoprotein glucotransferase (GT) 
which is located at ER exit sites and also found in the ERGIC (A. Helenius et al., 2004; 
Trombetta et al., 1998). This process occurs via the transfer of a glucose residue from UDP-
glucose to high mannose glycans bound to the protein intermediate (A. Helenius et al., 2004; 
Trombetta et al., 1998). Reglucoslated protein intermediates bind calnexin or calreticulin and 
go through the cycle again until complete folding is reached. Irreparably misfolded proteins 
are targeted for degradation by the ER-associated degradation (ERAD) pathway. These 
proteins are recognized by an intricate system involving ER mannosidase-1 which removes 
the terminal mannose residue from the trimannosyl pentapeptide backbone, resulting in the 
Man8GlcNac2 isoform (A. Helenius et al., 2004; Trombetta et al., 1998). Recognition of this 
isoform is mediated by a specific membrane-bound ER protein, Htm1/Mnl1 (an enzymatically 
inactive mannosidase homologue) also known as ER degradation-enhancing α-
mannosidase-like protein (EDEM) which is thought to chaperone proteins into the 
degradation and retro-translocation pathway as well as promoting the less specific mannose 
trimming by the ERAD pathway (Marin et al., 2012; Ron et al., 2011). This pathway ensures 






1.2.3.2 Direct effects of N-glycosylation mediated protein folding  
The direct involvement of N-glycans on protein folding has been reported extensively (A. 
Helenius, 1994; A. Helenius et al., 2001; Imperiali et al., 1999; Mitra et al., 2006; O'Connor 
et al., 1996; Wormald et al., 1999).  Addition of polar core oligosaccharide backbones 
(Figure 1.6) to glycoproteins increases their solubility. This results in the hydrophilic regions 
of the glycoprotein facing “outward” to the polar ER lumen, while the hydrophobic regions 
face “inward”. This entropic force allows the hydrophobic and hydrophilic residues to interact 
with their respective environments for efficient folding (Anthony, 2011; A. Helenius, 1994). 
This essentially alters the folding pathway by stabilizing secondary structures during folding 
while limiting the formation of equilibrium intermediates (Mitra et al., 2006). Furthermore, a 
direct effect by the N-acetyl group of the glycan residues of the attached glycan on the 
glycopeptide have been found to enhance β-turn formation (O'Connor et al., 1996). Upon 
inhibition of glycosylation during protein expression, proteins display an aggregated, 
misfolded and non-functional state (A. Helenius, 1994; Varki, 1993). Interestingly, 
deglycosylation of a mature protein has no effect on functionality, but reduces protein 
stability (Hagaman et al., 1998). This stabilization is thought to be due to the lack of mobility 
of unfolded conformations (A. Helenius et al., 2004).  When exploring the importance of 
individual glycosylation sites on this effect, some are found to be much more important than 
others, although a certain level of redundancy may be noticed, i.e. the importance of one site 
may be uncovered upon the removal of other sites (A. Helenius, 1994). Another interesting 
effect is the ability of N-glycans to cause a conformational shift upon glycan attachment 
(Imperiali et al., 1995). This shift forces the glycopeptide into a more rigid, thus more stable 
structure, resembling that of the mature protein (Imperiali et al., 1995). 
1.2.4 Glycosylation and proteolysis 
A number of studies have explored the ability of glycans to protect proteins from unregulated 
proteolysis (Beckham et al., 2012; Bernard et al., 1982; J. Fujihara et al., 2008; Hsiao et al., 




Berkel et al., 1995; Withka et al., 1993).  As previously mentioned, N-glycans are thought to 
promote the formation of β-turns (Mitra et al., 2006; O'Connor et al., 1996) and thus inducing 
a rigid conformation which may prevent proteolysis. An alternative mode of protection from 
proteolysis may be conferred by the presence of bulky glycans which may physically shield 
protease recognition sites (Anthony, 2011; Beckham et al., 2012; Bernard et al., 1982; J. 
Fujihara et al., 2008; Kretz et al., 1990; Nachon et al., 2002; Olden et al., 1982; Ripka et al., 
1993; van Berkel et al., 1995; Withka et al., 1993). Interestingly, N-glycans are thought to 
regulate the auto-proteolysis of the adhesion G protein-coupled receptor (GPCR), CD97 
(Hsiao et al., 2009). Thus, N-glycans may also be involved in the activation of adhesion-
GPCR.  
1.3 ACE GLYCOSYLATION 
ACE is heavily glycosylated (30% glycosylation by weight) with a total of 17 N-linked 
glycosylation sites, 10 of which are located on the N-domain and seven on the C-domain 
(tACE) (Figure 1.9 A) (Acharya et al., 2003; Anthony et al., 2010; Deddish et al., 1994; 
Gordon et al., 2003; O'Neill et al., 2008). Recombination studies have since shown that three 
N-terminal sites (sites 1, 2 and 3) are always glycosylated, sites 4, 5, 6 are partially 
glycosylated and site 7 is never glycosylated (Figure 1.9) (Anthony et al., 2010; Gordon et 
al., 2003). A study involving the construction of a wide range of tACE glycosylation mutants 
indicated that one or two of the N-terminal sites in tACE are important in secretion and 
folding of tACE (Figure 1.9 C) (Gordon et al., 2003). From these glycosylation mutants, tACE 
with glycosylation sites 1 and 3 (corresponding to sACE glycosylation sites 11 and 13) was 
able to be crystalized reproducibly (Figure 1.9 C) (Gordon et al., 2003). Another study on the 
N-domain indicated that glycosylation sites at C-terminus (sites 7, 8 and 9) were found to be 
crucial in the expression and folding of this domain. Notably, glycosylation mutant with only 
sites 3, 8 and 9 (Ndom3,8,9) was enzymatically active, while those with 7 and 9 (Ndom7,9), 




combination of glycosylation sites important for the expression of the N-domain (Figure 1.9 
B) (Anthony et al., 2010). 
 
  
Figure 1.7: Schematic representation of glycosylation sites on sACE and the individual domains. (A), sACE (B), N-domain and 
(C) C-domain. In A, all glycosylation sites are indicated with their respective Asn (N) residue numbers on sACE. In B, minimally 
glycosylated N-domain mutants, Ndom7,8,9 and Ndom3,8,9 are indicated. In C, minimally glycosylated C-domain mutants, Cdom11,12 
and Cdom11,13 are indicated. Glycosylation sites are numbered according to the sequence the full-length sACE. Black box – intact 
glycosylation site; open box – mutated glycosylation sites; grey box – Represents overlapping sequence common to both domains (inter-




1.3.1 ACE glycosylation and crystallization 
Rational drug design relies heavily on protein crystallization for the structure-based design of 
potent and selective inhibitors. The degree of flexibility and heterogeneous composition of 
glycans often interferes with protein-crystal formation making glycosylation a major hurdle in 
crystallization studies (Butters et al., 1999). As previously mentioned, glycosylation is crucial 
for protein expression. Manipulation of glycosylation sites is usually employed to obtain 
reproducibly crystallisable protein isoforms. However, lack of intact glycosylation sites may 
produce inactive or misfolded proteins which essentially cannot be purified for 
crystallography trials. Therefore, manipulation of glycoproteins in the aim to acquire the 
crystal structure is very limited as is the case with ACE. Currently, crystallization of the full-
length somatic ACE has not yet been achieved, due to the high degree of glycosylation and 
also due to the flexibility conferred by the linker region between the two domains. One 
approach to develop the crystal structure of the individual domains of ACE has proved to be 
highly successful. As mentioned in section 1.1.1.2, crystal structures of the N- and C-domain 
have been solved through extensive manipulation of glycans on these domains, creating 
minimally glycosylated constructs (Anthony et al., 2010; Gordon et al., 2003). 
1.3.2 ACE glycosylation and expression 
Glycosylation is known to play a crucial role on the proper folding of ACE (see section 1.2.3). 
The glycosylation requirements sufficient for protein folding vary considerably among 
different cell types. Expression of ACE in Escherichia coli resulted in inactive protein 
(Sadhukhan et al., 1996), due to the lack of glycosylation machinery in these cells. As 
mentioned in section 1.3, elegant recombination studies have identified the minimum 
glycosylation requirements of the N- and C-domains of ACE in Chinese hamster ovary 
(CHO) cells (Anthony et al., 2010; Gordon et al., 2003). However, not all mammalian cell 
types share the same protein glycosylation requirements (Croset et al., 2012). Additionally, 
certain proteins have significant differences in the glycan composition, size, quantity and the 




tACE with mutated glycosylation sites or in the presence of a glycosylation inhibitor in HeLa 
cells resulted in inactive proteins that were rapidly degraded by the proteasome (Gordon et 
al., 2003; Sadhukhan et al., 1996). Interestingly, tACE with only glycosylation site 3, which 
suffered the same fate in HeLa cells, was properly processed in yeast cells (Sadhukhan et 
al., 1996). Furthermore, a pilot study exploring the expression of the N-domain in yeast cells 
revealed very low levels of Ndom3,8,9 (unpublished data) (Figure 1.9). Interestingly 
Ndom3,8,9 was sufficiently expressed in CHO cells (Anthony et al., 2010). 
1.3.2 ACE glycosylation and stability 
When looking at the stability of ACE, two points have to be considered; the thermal stability 
and; the apparent structural integrity. Focusing on the thermal stability, ACE has been 
shown to have two distinct melting temperatures (Tm) at 55°C and 72°C, corresponding to 
the Tm values of the individual domains, the higher value being that of the N-domain and the 
lower value being that of the C-domain (Voronov et al., 2002). This difference in the Tm of 
the individual domains was initially thought to be a result of the high proline content present 
in 29-133 amino acid sequence of the N-domain, in comparison to corresponding amino acid 
sequence, 633-734 in the C-domain, and/or the α-helical content found in the same region 
which is much higher in the N-domain than in the C-domain (Voronov et al., 2002). It is now 
known that the most critical contributor to the thermal stability of ACE, and thus the individual 
domains, is the presence of N-linked glycans (Anthony et al., 2010; Gordon et al., 2003; 
O'Neill et al., 2008; Voronov et al., 2002). This is evidenced by the sequential removal of 
glycosylation sites on the N- and C-domain showing that with decrease in the number of 
glycans, there is a subsequent decrease in the Tm (Anthony et al., 2010; Gordon et al., 
2003; Natesh et al., 2003; O'Neill et al., 2008). It is now known that ACE relies on the N-
domain to maintain a high Tm (Honours Thesis, 2011). With regards to the apparent 
structural integrity, ACE is known to be susceptible to minor levels of limited proteolysis in 
the inter-domain linker region (Deddish et al., 1994; Sturrock et al., 1997). A minimally 




2011) suggesting that N-glycosylation plays a crucial role in protecting ACE from proteolysis 
(see section 1.3.4). 
1.4 AIMS AND OBJECTIVES 
The role N-linked glycosylation on the N- and C-domain has been well described, however, 
little is known about the relevance of glycosylation on the structure and function of sACE. 
Initial attempts to investigate the role of N-glycosylation on sACE resulted in an increased 
susceptibility to inter-domain linker proteolysis and reduction in the expression.  The aim of 
this work was to a) strategically generate a panel of sACE glycosylation mutants that would 
be used to b) investigate the importance of N-linked glycosylation on the stability and 
functionality of sACE, and c) determine the minimal glycosylation requirements for a stable 
enzymatically active sACE construct.  
These aims will be addressed by: 
1) Generating sACE constructs of varying degrees of glycosylation (Chapter 2). 
2) Investigating the role of N-glycan site occupancy on inter-domain linker proteolysis 
(Chapter 3). 
3) Determining the cellular location and rate of inter-domain linker proteolysis (Chapter 
4). 
4) Investigating the role of N-glycans on the expression and thermal stability of sACE 





Chapter 2: DNA Manipulation 
2.1 INTRODUCTION  
Elegant work has been done to study the individual domains of sACE by generating mutants 
lacking glycosylation sites using PCR-based SDM (see section 1.3) (Anthony et al., 2010; 
Gordon et al., 2003). Here, N-glycan attachment was prevented by converting the 
asparagine in the glycosylation site recognition motif (Asn-Xxx-Ser/Thr) to a glutamine. MG-
sACE constructs were generated by combining some of these with previously generated 




These were used as subcloning templates for generating novel MG-sACE mutants for the 
purpose of investigating the effect of N-glycan site occupancy on protection from inter-
domain linker proteolysis, expression and thermal stability. An sACE mutant with a H600C 
substitution has previously been generated and characterized (Gordon, 2011). This mutant 
formed a disulphide bridge between Cys600 and Cys474 located in the N-domain. This 
interaction limits flexibility caused by the linker region, and may prevent inter-domain linker 
Figure 2.1: Diagrammatic representation of previously generated MG-sACE mutants. Black boxes indicate intact 
glycosylation sites and white boxes indicate sites that are not glycosylated. Numbers indicate glycosylation site positions. 
*Mutants generated by Anthony (2011). 
‡





proteolysis in MG-sACE mutants. To this end, an MG-sACE mutant containing a H600C 
substitution was also generated.  
2.2 EXPERIMENTAL METHODS  
2.2.1 Materials 
Restriction enzymes AgeI, KpnI, PvuI, Eco47III, SacI, EcoRI, BamHI, NotI, XbaI, Eco91I, T4 
DNA ligase and O'GeneRuler™ DNA Ladder were obtained from Fermentas (Waltham, MA, 
USA). Restriction enzymes RcaI and EcoRV were obtained from Roche Ltd. (Basel, 
Switzerland). The GeneJET Gel Extraction Kit was purchased from Thermo Scientific 
(Wilmington, USA). E.coli DH5 α cells were purchased from Promega (Madison, WI, USA). 
Microcentrifuge 5424R (Eppendorf, Hamburg, Germany) was used for centrifugations.   
2.2.2 Subcloning of novel MG-sACE constructs 
ACE Plasmids sACE2,3,6,8,9/11,13; sACE2,3,8,9/11,13; sACE3,6,9/11,12; sACEH600C; 
Ndom3,8,9 all in pcDNA3.1(+) and WT-sACE in pBSK(+) were used as templates.  
2.2.2.1 Restriction enzyme digest and agarose gel electrophoresis 
Templates were digested with relevant restriction enzymes and DNA fragments were 
electrophoresed at 70 V for 1 hour. Vector and insert fragments were excised and purified 
using the GeneJET Gel Extraction Kit according to the manufacturer’s instructions. DNA 
concentrations were determined using a NanoDrop™ 1000 spectrophotometer (Thermo 
Scientific, Wilmington, USA). 
2.2.2.2 Ligation 
Vector and insert fragments were ligated in a 3:1 insert to vector ratio using 1U T4 DNA 
ligase and 1X T4 DNA ligase buffer (Fermentas, Waltham, MA, USA) in a final volume of 20 





2.2.2.3 Transformation of competent cells 
From each ligation mix, 10 µl was added to 100 µl of competent DH5 α cells followed by a 
20 minute incubation on ice. Cells were heat shocked at 42°C for 1 minute, followed by 1 
minute incubation on ice. To the transformation mix, 450 µl of Luria broth (LB) was added 
and then incubated at 37°C for 1 hour. 100 µl of the LB-transformation mix was plated out on 
a Luria agar (LA) plate containing 50 µg/ml ampicillin and incubated overnight at 37°C. 
2.2.2.4 Crude Plasmid DNA isolation and for positive clone screening 
DNA was isolated from resistant clones using the STET boiling-mini lysate method (Ehrt et 
al., 2003). Cultures were incubated at 37°C overnight and transferred to 1.5 ml Eppendorf 
tubes for centrifugation at 12000xg. The resultant supernatants were removed leaving the 
bacterial pellets which were resuspended in 250 µl of STET (8% (w/v) sucrose; 5% (w/v) 
triton X-100; 50 mM EDTA; 50 mM TRIS, pH 8.0) containing 1 mg/ml of lysozyme. 
Suspensions were boiled for 1 minute and promptly centrifuged for 15 minutes at 12000xg. 
The resultant pellet was removed with a sterile toothpick and discarded. An equal volume of 
isopropanol was then added to each of the tubes and mixed by inversion then centrifuged at 
12000xg for 10 minutes. The resultant supernatants were removed and DNA pellets were 
left to air-dry for approximately 10 minutes. Plasmid DNA was then resuspended in 20 µl of 
1/10 Tris EDTA (1.0 mM Tris-HCl, 0.1 mM EDTA, pH 7.4) and heated at 68°C for 10 minutes 
to ensure complete solubilisation. DNA constructs were screened by digestion to determine 
the presence/absence of introduced/removed restriction sites with the relevant restriction 
enzymes according to recommended conditions. Digest products were visualized on 1% 
(w/v) agarose gels containing 0.3 μg/ml ethidium bromide. 
2.2.2.5 Plasmid DNA preparation for sequencing 
Positive clones were picked into 3 ml LB containing 50 µg/ml ampicillin, and incubated at 




Miniprep Kit (Thermo Scientific, Wilmington, USA) as per manufacturer’s instructions. DNA 
concentrations were determined as described in section 2.2.2.1.  
2.2.2.6 DNA sequencing to confirm the presence of mutations in recombinant sACE 
constructs 
All novel sACE constructs were sequenced to confirm the presence of the engineered 
mutations. This was done by capillary sequencing conducted at the Central Analytical 
Facility (CAF) (Stellenbosch University, South Africa) with the 5500xl SOLiD™ System 
Genome analyser, using internal sACE sequencing primers (Appendix A1) and a T7 
promoter primer. 
2.2.2.7 Up-scaled plasmid DNA preparation for transfection 
A 100 µl of positive plasmid containing DH5 α cultures were seeded into 50 ml LB containing 
50 µg/ml ampicillin, and incubated at 37°C overnight with shaking. DNA was isolated using 
the Qiagen Plasmid Midi Kit (Qiagen, Hilden, Germany) as per manufacturer’s instructions. 
DNA concentrations were determined as described in section 2.2.2.1. 
2.3 RESULTS 
MG-sACE constructs were assembled in pcDNA3.1(+) for expression in mammalian cells 
(Figure 2.2). Here, restriction sites previously engineered to facilitate subcloning of the N-
domain (Anthony, 2011), intrinsic sACE restriction sites and the pcDNA3.1(+) multiple 
cloning sites  were used to obtain fragments containing  glycosylation sites of interest. 
Codons responsible for the translation of the asparagine to which a sugar will be attached 
are represented by AAC/T, those mutated to a glutamine to inhibit sugar attachment are 








Figure 2.2: Cloning strategies used to generate MG-sACE isoforms. All constructs were assembled in pcDNA3.1(+). A) sACE3,6,9/12,13; B) 
WT-sACE, C) sACEH600C; D) Ndom3,8,9; E) sACE2,3,8,9/11,13 and F) sACE2,3,6,8,9/11,13 were used as templates to generate a total of six 
novel MG-sACE mutants. G) sACEWTNdom/12,13 was constructed using sACEWTNdom and sACE12,13pcDNA3.1(+) fragments obtained from a 
BamHI/AgeI digest. H) sACE3,6,9/WTCdom was constructed using sACEWTCdom and sACE3,6,9pcDNA3.1(+) fragments obtained from a 
AgeI/EcoRV digest. I) sACE3,6,9/H600C/12,13 was constructed using sACE3,6,9, H600C and sACE12,13pcDNA3.1(+) fragments obtained from a 
AgeI/XhoI digest. J) sACE3,8,9/12,13 was constructed using Ndom3,8,9 and sACE12,13pcDNA3.1(+) fragments obtained from a Eco91I/KpnI 
digest. K) sACE2,3,8,9/12,13 was constructed using sACE2,3,8,9 and sACE12,13pcDNA3.1(+) fragments obtained from a KpnI/Age/KpnI digest. 
L) sACE2,3,6,8,9/12,13 was constructed using sACE2,3,6,8,9 and sACE12,13pcDNA3.1(+) fragments obtained from a KpnI/Age/KpnI digest. Black 




2.3.1 Cloning of minimally glycosylated sACE mutants to investigate the 
stability of the linker region 
Firstly, wild-type domains were substituted with MG N- and C-domains to help give an 
indication of which domain contains protective N-glycans (see Chapter 3). MG-sACE 
constructs were then strategically generated by manipulating glycosylation sites proximal to 
the inter-domain linker region, while preserving sites that have been shown to be crucial for 
the expression of the individual domains.  Of the available DNA recombination techniques 
available, subcloning was opted due to its simplicity and the reduced chances of introducing 
PCR-based spurious mutations (see section 2.4).  
2.3.1.1 Construction of sACEWTNdom/12,13 
As previously mentioned, to help identify in which domain resides the protective N-glycans, a 
MG N-domain was substituted with a WT N-domain to generate 
sACEWTNdom/12,13pcDNA3.1(+). Constructs WTsACEpBSK(+) and 
sACE3,6,9/12,13pcDNA3.1(+) were used as templates. These were digested as indicated in 
Figure 2.3.  
 
Figure 2.3 Schematic showing subcloning strategy of sACEWTNdom/12,13pcDNA3.1(+). 
Restriction enzymes BamHI and AgeI were used to cut out a 1717 bp WT N-domain insert and a 
7724 bp vector fragment containing the C-domain and pcDNA3.1(+) with glycosylation sites 12 






Successful subcloning was confirmed by restriction enzyme digests (Figure 2.4 A, B) and 
DNA sequencing (Figure 2.4 C, D), where the incorporation of site 5 results in the removal of 
an AflII restriction site at position 1401 while the absence of site 15 results in the addition of 
an EcoR1 restriction site at position 3787. All the expected bands were observed in Figure 
2.4 A and B, although the 305 bp and 314 bp fragments appear to be approximately 500 bp. 
This is possibly due to an electrophoretic mobility shift caused by increased binding of the 
restriction enzyme to the DNA  without dissociating before and/or  during electrophoresis 
(Makela et al., 2012), thus resulting in a band appearing higher than expected. However, 
DNA sequencing did confirm the presence of site 5 (Figure 2.4 C), indicating the fully-
glycosylated status of the N-domain, and the absence of site 15 (Figure 2.4 D), indicating the 
hypo-glycosylated status of the C-domain. No discrepancies were found in the entire 
plasmid. An additional EcoRI restriction site is present at position 4656 and is a result of 




Figure 2.4: Vector diagram, restriction enzyme digests and electrophoretogram of 
sACEWTNdom/12,13pcDNA3.1(+). A) Construct was digested with AflII and NotI, with 
expected fragments of 5358 bp, 3783 bp and 305 bp. B) Construct was digested with EcoRI, 
with expected fragments of 5428 bp, 2835 bp, 869 bp, 314 bp. C) Electrophoretogram showing 
the presence of glycosylation site 5. D) Electrophoretogram showing the absence of 
glycosylation site 15. Black star indicates a mutated restriction site. 1 – O’generuler DNA 




2.3.1.2 Construction of sACE3,6,9/WTCdom 
A MG C-domain was also substituted with a WT C-domain to generate 
sACE3,6,9/WTCdompcDNA3.1(+) using WTsACEpBSK(+) and 
sACE3,6,9/12,13pcDNA3.1(+) as templates. Constructs were digested as indicated in Figure 
2.5.  
 
Residual undigested DNA is observed migrating at approximately 10 kb (Figure 2.6 A, B). 
However, the expected banding pattern is observed indicating absence of site 5, evidenced 
by the presence of an AflII restriction site at position 1401 (Figure 2.6 A), and the presence 
of site 15 (Figure 2.6 B), evidenced by the absence of an EcoRI restriction site at position 
3787. Furthermore, electrophoretograms in Figure 2.6 C and D indicate the 
presence/absence of the respective sites, thus confirming successful incorporation of a fully-
glycosylated C-domain.  
  
Figure 2.5 Schematic showing subcloning strategy of sACE3,6,9/WTCdompcDNA3.1(+). 
Restriction enzymes AgeI and EcoRV were used to cut out a 2329 bp WT C-domain insert and 
a 7117 bp vector fragment containing the N-domain and pcDNA3.1(+) with glycosylation sites 






Figure 2.6: Vector diagram, restriction enzyme digests and electrophoretograms of 
sACE3,6,9/WTCdompcDNA3.1(+). A) Construct was digested with AflII and NotI, with expected 
fragments of 5358 bp, 3290 bp and 493 bp and 305 bp. B) Construct was digested with EcoRI, with 
expected fragments of 5428 bp, 4018 bp. C) Electrophoretogram showing the absence of 
glycosylation site 5. D) Electrophoretogram showing the presence of glycosylation site 15. Black star 
indicates a mutated restriction site.  1 – O’generuler DNA ladder mix; 2 – sACE3,6,9/WTCdom 
pcDNA3.1(+). 
 
2.3.1.3 Construction of sACE3,8,9/12,13 
Since a number of MG-sACE mutants with varying intact glycosylation sites proximal to the 
inter-domain linker region have been generated (see Figure 2.1), an additional mutant, 
sACE3,8,9/12,13pcDNA3.1(+), needed to be generated to investigate the effect of this 
combination of intact glycosylation sites on protection from linker proteolysis. This was 
generated using Ndom3,8,9pcDNA3.1(+) and sACE3,6,9/12,13pcDNA3.1(+) as templates. 









Restriction enzyme digests were conducted and the resultant banding pattern observed 
confirms that an RcaI digestion produces an additional fragment of 1270 bp (Figure 2.8 A). 
This is due to reintroduction of site 3 which results in the addition of an RcaI restriction site at 
position 1182. Similarly, digestion with PvuI produces a linearized plasmid (Figure 2.8 B) 
which is due to the reintroduction of site 8 that results in the removal a PvuI restriction site at 
position 2292. Furthermore, DNA sequencing confirmed the presence of both site 3 (Figure 




Figure 2.7 Schematic showing subcloning strategy of sACE3,8,9/12,13pcDNA3.1(+). 
Restriction enzymes KpnI and Eco91I were used to cut out a 1981 bp N-domain insert 
containing glycosylation sites 3, 8 and 9, and a 7465 bp vector fragment containing the C-
domain and pcDNA3.1(+) with glycosylation sites 12 and 13. 1 – O’generuler DNA ladder mix; 





2.3.1.4 Construction of sACE3,6,9/H600C/12,13 
Due to the lack of compatible restriction sites for subcloning and technical difficulties 
encountered with PCR based SDM (see section 2.4), a more complex strategy was needed 
to be employed for generating sACE3,6,9/H600C/12,13pcDNA3.1(+). This involved a two-
step subcloning strategy which allowed for the incorporation of a segment containing coding 
region for the H600C substitution. Constructs  sACE3,6,9/12,13pcDNA3.1(+) and 
sACEH600CpcDNA3.1(+) (Gordon, 2011) were used as templates which were digested as 
indicated in Figure 2.9. Three bands of interest (V1, V2 and H600C) were excised, purified 
and ligated as described in section 2.2.2. Firstly, fragments of 7094 bp containing the N-
domain with glycosylation sites 3, 6 and 9 and pcDNA3.1(+) (V1) and the H600C fragment 
from the AgeI/XhoI digestion of sACEH600CpcDNA3.1(+)  were ligated (Figure 2.9).  
 
 
Figure 2.8: Vector diagram, restriction enzyme digests and eletrophoretograms of 
sACE3,8,9/12,13pcDNA3.1(+). A) Construct was digested with RcaI, with expected fragments 
of 7171 bp, 1270 bp and 1008 bp. B) Construct was digested with PvuI which resulted in the 
linearization of the construct. C) Electrophoretogram showing the presence of glycosylation 
site 3. D) Electrophoretogram showing the presence of glycosylation site 8. Black star indicates 





In Figure 2.10 A, a BsaXI digest showed some residual undigested DNA at approximately 10 
kb, but the expected banding pattern resulting in the presence of an additional BsaXI 
restriction site is observed, indicating the successful incorporation of H600C. Double bands 
were noticeable at the 1893 bp, 724 bp and 471 bp sized fragments and this is likely due to 
a reduced efficiency of the restriction enzyme resulting in star activity (Selin et al., 2013). 
The same pattern is noticed upon digest of negative controls sACEH600CpcDNA3.1(+) and 
sACE3,6,9/12,13pcDNA3.1(+) (Figure 2.11). Furthermore, DNA sequencing was done to 
confirm the sequence of the ligation product (Figure 2.10 B).  V1/H600CpcDNA3.1(+) was 




Figure 2.9 Schematic showing subcloning strategy of 
sACE3,6,9/H600C/12,13pcDNA3.1(+). Restriction enzymes AgeI and XhoI were used to cut 
out fragments of 7094 bp (containing the N-domain with glycosylation sites 3, 6 and 9 and 
pcDNA3.1(+) (V1)) and a 1735 bp fragment (containing the C-domain with glycosylation sites 
12 and 13) (V2)) from sACE3,6,9/12,13pcDNA3.1(+). A 617 bp fragment containing the H600C 
substitution (dashed curve) was obtained from sACEH600CpcDNA3.1(+). 1 – O’generuler DNA 





Successful subcloning was then confirmed by digestion with BsaXI as indicated in Figure 
2.11. The banding pattern clearly indicates that sACE3,6,9/H600C/12,13 is a combination of 
sACE3,6,9/12,13 and sACEH600C.    
 
  
Figure 2.10: Vector diagram, restriction enzyme digest and electrophoretogram 
of V1/H600CpcDNA3.1(+). A) V1/H600CpcDNA3.1(+) was digested with BsaXI, with 
expected fragments of 3606 bp, 1893 bp, 1014 bp, 724 bp and 471 bp. B) 
Electrophoretogram showing the presence of the H600C substitution. 1 – O’generuler 
DNA ladder mix; 2 – V1/H600CpcDNA3.1(+).  
Figure 2.11: Vector diagram and restriction enzyme digest of 
sACE3,6,9/H600C/12,13pcDNA3.1(+) including negative controls 
sACE3,6,9/12,13pcDNA3.1(+) and sACEH600CpcDNA3.1(+). Constructs were digested with 
BsaXI, with expected fragments for sACE3,6,9/12,13pcDNA3.1(+) being at 3606 bp, 1994 bp, 
1893 bp, 755 bp, 724 bp and 471 bp. 1 – O’generuler DNA ladder mix; 2 – 





2.3.2 Cloning of minimally glycosylated sACE mutants to investigate thermal 
stability 
In order to assess the effect of N-glycan site occupancy on sACE expression and thermal 
stability, glycosylation sites had to be reintroduced into available MG-sACE mutants. To this 
end, sequential addition of specific glycosylation sites previously shown to be important for 
the expression of ACE was employed. A study on the N-domain revealed that removal of site 
1 did not greatly alter the thermal stability while removal of site 2 caused a great loss in 
thermal stability (Anthony, 2011). Thus, reintroduction of site 2 to MG-sACE was employed 
to investigate its effect on full-length sACE.  
2.3.2.1 Construction of sACE2,3,8,9/12,13 
To generate sACE2,3,8,9/12,13pcDNA3.1(+), sites 2, 3, 8 and 9 were subcloned from 
sACE2,3,8,9/11,13pcDNA3.1(+) and ligated with sites 12 and 13 from 
sACE3,6,9/12,13pcDNA3.1(+). Constructs were digested as indicated in Figure 2.12.  
Figure 2.12 Schematic showing subcloning strategy of sACE2,3,8,9/12,13pcDNA3.1(+). 
Restriction enzymes KpnI and AgeI were used to cut out a 1747 bp N-domain insert containing 
glycosylation sites 2, 3, 8 and 9, and a 7712 bp vector fragment containing the C-domain and 
pcDNA3.1(+) with glycosylation sites 12 and 13. 1 – O’generuler DNA ladder mix; 2 – 






Successful incorporation of site 2 was confirmed by the observed banding pattern from an 
Eco47III digest which produces two fragments of 8059 bp and 1357 bp (Figure 2.13 A). This 
is due to silent mutation resulting in the knock-out of an Eco47III restriction site at position 
1138 when site 2 is reintroduced. The appropriate sequence for an intact glycosylation site 2 
was also observed (Figure 2.13 B). 
 
 
2.3.2.2 Construction of sACE2,3,6,8,9/12,13 
A second mutant was generated similarly to the above-mentioned  using 
sACE2,3,6,8,9/11,13pcDNA3.1(+) and sACE3,6,9/12,13pcDNA3.1(+). Constructs were 
digested as indicated in Figure 2.14 and sACE2,3,6,8,9 pcDNA3.1(+) and sACE12,13 were 
ligated yielding, sACE2,3,6,8,9/12,13pcDNA3.1(+). 
 
Figure 2.13: Vector diagram, restriction enzyme digest and 
electrophoretogram of sACE2,3,8,9/12,13pcDNA3.1(+). A) Construct was 
digested with Eco47III, with expected fragments of 8059 bp and 1387 bp. B) 
Electrophoretogram showing the presence site 2. Black star indicates a mutated 





Figure 2.14 Schematic showing subcloning strategy of sACE2,3,6,8,9/12,13pcDNA3.1(+). 
Restriction enzymes KpnI and AgeI were used to cut out a 1747 bp N-domain insert containing 
glycosylation sites 2, 3, 6, 8 and 9, and a 7712 bp vector fragment containing the C-domain 
and pcDNA3.1(+) with glycosylation sites 12 and 13. 1 – O’generuler DNA ladder mix; 2 – 




Subcloning was confirmed as with sACE2,3,6,8,9/12,13 where the successful incorporation 
of site 2 was evidenced by the appropriate DNA sequence (Figure 2.15 B) and the  banding 











Figure 2.15: Vector diagram, restriction enzyme digest and electrophoretogram of 
sACE2,3,6,8,9/12,13pcDNA3.1(+). A) Construct was digested with Eco47III, with 
expected fragments of 8059 bp and 1387 bp. B) Electrophoretogram showing the 
presence site 2. Black star indicates a mutated restriction site. 1 – O’generuler DNA 





The aim of this study was to generate novel MG-sACE constructs geared towards 
investigating the effect of N-glycan site occupancy on protection from inter-domain linker 
proteolysis, expression and thermal stability. Furthermore, a disulphide bridge was 
engineered between the linker region and the N-domain by introducing the amino acid 
substitution H600C. The subcloning approach used was much more favourable than SDM 
(see section 2.4) due to its simplicity, efficiency and reliability. A detailed background 
discussion on the rationale behind the design of each mutant will be covered in Chapters 3 
and 4. In brief, the design of these mutants was based on the preservation of previously 
described key glycosylation sites on the individual domains (Anthony et al., 2010; Gordon et 
al., 2003). This was important to avoid obtaining possibly misfolded and inactive sACE 
proteins during expression. The library of generated mutants (Figure 2.16) share a degree of 
overlap between the aims of this project.  Meaning, constructs generated for addressing the 
role of N-glycan site occupancy on limited proteolysis were also required to assess the effect 
of site occupancy on the stability and expression, and vice versa (see Chapter 3 and 4). 
  
Figure 2.16: Diagrammatic representation of generated MG-sACE mutants. Black boxes indicate intact glycosylation sites 
and white boxes indicate sites that are not glycosylated. Dashed line indicates position of the H600C mutation. Numbers 




A few anomalies were noticed in some agarose gels. In Figures 2.4, 2.6 and 2.10, residual 
undigested DNA was observed. Several factors may be responsible for this observation. 
Firstly, restriction enzymes may be less efficient due to suboptimal conditions caused by 
improper enzyme dilutions, excessive DNA content or less efficient buffering, especially 
during double digests where a certain buffer may be 100% optimal for one enzyme while 
only displaying 50-100% for another. Furthermore, contamination caused by impurities in the 
buffer, water and enzyme solution may be affecting enzyme activity. Additionally, reduced 
incubation time usually results in incomplete DNA digestion. Figure 2.4 A and B displayed an 
electrophoretic mobility shift of approximately 300 bp to approximately 500 bp. This 
phenomenon has been widely reported and forms the basis of the electrophoretic mobility 
shift assay used to study DNA-protein interactions (Makela et al., 2012). Furthermore, 
RNase A, which is used to during DNA purification, has been shown to cause gel-shifts 
(Huhtanen et al., 2012). Unexpected bands were observed migrating below bands of interest 
in Figures 2.10 A and 2.11. This was possibly due to BsaXI star activity caused by reduced 
enzyme efficiency due to improper storage and handling conditions. Six MG-sACE (Figure 
2.16) mutants were successfully generated and found to contain no aberrant mutations from 
DNA sequencing data. Furthermore, the desired codons for Asn (AAC/T), Gln (CAG) and 
Cys600 (TGC) translation were observed.  
 
Initial attempts to generate mutants using PCR based SDM were hindered by some 
technical difficulties;  
Firstly, SDM yielded no product from several reactions using modified protocols of a 
standard PCR kit (Kapa HiFi PCR kit (Kapa Biosystems, Cape Town, South Africa)). This is 
usually a result of lack of primer annealing. Preferential annealing of mutagenic primers is 
essential for ensuring the incorporation of the desired mutation, and this usually requires 
optimization. Therefore an annealing temperature gradient PCR was done, however, no 




Touch-down PCR which lowers the primer annealing temperature within a desired range 
after each cycle, thus increases reaction efficiency at lower annealing temperatures, while 
increasing the specificity at higher annealing temperatures. This too resulted in no product. 
This was possibly due to the cumbersome nature of the sACE gene in pcDNA3.1(+). The 
entire plasmid has a molecular weight of almost 10 kb, and it is known that large 
oligonucleotides may be problematic during the denaturing, annealing and extension steps 
(Ling et al., 1997; B. Shen, 2002). Additionally, PCR on large plasmids is prone to increased 
spurious mutations that may occur due to slippage of Taq polymerase, especially with an 
increase in PCR cycles (Ling et al., 1997). Due to these problems, PCR-based methods 
were abandoned. Subcloning on the other hand proved to be much more beneficial and less 
tedious with the exception of one difficulty encountered. Finding compatible restrictions sites 
proved to be challenging as sACE and individual domain constructs that have been 
generated previously lack some of the restriction sites in the multiple cloning site of the 
vectors in which they are inserted. This is due to the several sub/cloning experiments that 
have been carried out in the group, where some of the restriction sites were lost. 
Furthermore, considering the fact that MG-sACE constructs have restriction sites 
added/removed upon each glycosylation site alteration, some restriction sites that were 
engineered to facilitate subcloning for a particular study previously, were not compatible with 
this study. Thus, a degree of manoeuvring between constructs and multiple restriction 




Chapter 3: Investigating the effect of N-glycan site 
occupancy on inter-domain linker proteolysis 
3.1 INTRODUCTION  
Great strides have been made in the rational drug design of domain selective ACE inhibitors. 
These have relied heavily on the availability of high resolution crystal structures of the N- 
and C-domain (see section 1.1.2). However, these structures provide little insight into the 
previously described cooperativity between the two domains of sACE (Binevski et al., 2003; 
Friborg et al., 2002; Woodman et al., 2005). To date, the high resolution 3D structure of 
sACE has been elusive (see section 1.1.2). Solving the structure would aid in a better 
understanding of the functional and structural properties of the full-length sACE with regards 
to domain cooperativity, and the design of more potent and selective ACE inhibitors. As 
mentioned in Chapter 1, initial attempts to generate a suitable MG-sACE candidate for X-ray 
crystallography involved the combination of previously crystallized individual domains to 
yield sACE3,8,9/11,13 (Figure 3.1). Unfortunately, this glycosylation mutant was susceptible 
to limited proteolysis in the inter-domain linker region (Anthony, 2011), suggesting that 
removal of N-glycans rendered sACE susceptible to attack by an as yet unknown protease. 
Thus, a logical approach was to reintroduce N-glycans which are proximal to the inter-
domain linker region in sACE3,8,9/11,13, in order to identify those crucial for preventing 
proteolysis. Identifying these key N-glycans is likely to aid in generating a stable MG-sACE 







Figure 3.1: Two and three-dimensional representations of WT-sACE and sACE3,8,9/11,13 showing N-glycan site 
occupancy. A) Three-dimensional WT-sACE model of combined individual domain crystal structures. Glycosylation sites that are 
not glycosylated are faded. B) Two-dimensional WT-sACE model. C) Two-dimensional sACE3,8,9/11,13 model. Glycosylation sites 
are numbered starting from the N-domain. Glycosylation sites proximal the inter-domain linker region are indicated by grey circles. 







1) To determine the effect of N-glycan site occupancy on inter-domain linker proteolysis of 
minimally glycosylated somatic ACE. 
3.2 EXPERIMENTAL METHODS 
3.2.1 Transient transfection and expression of MG-sACE mutants in CHO cells 
Chinese hamster ovary K1 (CHO-K1) cells were seeded into 6 well plates in complete 
growth medium (43% DMEM, 43% F-12 HAMS, 20 mM HEPES pH 7.5), supplemented with 
10% fetal calf serum (FCS) which was heat inactivated at 56°C for 30 minutes, then 
incubated at 37°C in 5% CO2 to reach approximately 50-80% confluence in 24 hours. Cells 
were transfected in triplicate or more with template DNA inserted in pCDNA3.1(+) (including 
a H2O mock and a WT-sACE control) using the liposome method (GeneJuice® Transfection 
Reagent liposome method (Novagen)) as per manufacturer’s instructions. Cell lysates and 
media were collected 24-72 hours post transfection for analysis. 
3.2.2 Enzymatic activity determination via Z-Phe-His-Leu (Z-FHL) fluorimetric 
assay 
To confirm successful transfection, ACE enzymatic activity was determined from harvested 
media and lysates using a Z-FHL fluorimetric assay, based on the Hippuryl-His-Leu (HHL) 
fluorimetric assay (Friedland and Silverstein in 1976). Assays were carried out using 
triplicate repeats for each sample collected from media and lysates. To 3 wells in a 96 well 
plate, 6 µl of each sample (in 2% FCS medium) was added. To these sample containing 
wells, 30 µl of a 1 mM Z-FHL working solution was then added, including an empty zero-
blank-time (ZBT). These were incubated at 37°C for 15 – 30 minutes with shaking, to 
promote cleavage of Z-FHL. Following incubation, the reaction was stopped with 120 µl of 
0.4 M NaOH per well. To the ZBT wells, 3 µl of medium/lysate was added and allowed to 
shake thoroughly. The cleaved product from the reaction was derivatized by the addition of 




incubation for 10 minutes at room temperature with shaking in the dark. Derivitization was 
halted by the addition of 30 µl of a 3 M HCl solution. The fluorescence was measured at the 
excitation wavelength of λEx=360nm and the emission wavelength of λEm=485nm in the Cary 
Eclipse Fluorimeter (Varian CA, USA). The fluorescent units (FU) were converted to enzyme 
activity in mU/ml/min using the HHL standard curve (Appendix A3), representative of the 
nmols of HL produced per ml of sample, per minute. Each of the activity values were 
calculated accordingly, considering both incubation period and the volume of sample added. 
3.2.3 Sample preparation using lisinopril affinity resin 
Samples displaying ACE activity were concentrated using Lisinopril-Sepharose beads 
(Lisinopril is a strong non-domain selective competitive inhibitor of sACE). Briefly, 60 µl of a 
Lisinopril-Sepharose resin prepared in wash buffer (20 mM HEPES, 800 mM NaCl (pH 7.5)) 
was added to 250 µl of media/lysates and vortexed for 30 minutes. Samples were then 
centrifuged at 12000xg for 5 minutes. The resultant supernatant was promptly discarded and 
the ACE-lisinopril pellet was resuspened with 20 µl wash buffer. 
3.2.4 Western blotting and densitometry 
Samples were electrophoresed in sodium dodecyl sulphate polyacrylamide gel using 
standard lab protocol (Appendix A4). Following electrophoresis, the protein was transferred 
from the gel to Hybond-ECL nitrocellulose membranes (Amersham, Buckinghamshire, UK) in 
blotting buffer (0.5 M Tris, 1.44% (w/v) glycine, and 0.2% (v/v) methanol) at 100 V for 1 hour. 
Membranes were then incubated in blocking buffer (5% (w/v) skim milk, 0.1% (v/v) Tween-
20, 0.2 M NaCl, 0.05 M Tris-HCl (pH7.4)) overnight at 4°C, to prevent non-specific binding 
upon antibody incubation. Membranes were then incubated for 1.5 hours with the 
monoclonal rat anti-ACE primary antibody 4G6 (Balyasnikova et al., 2003; Balyasnikova et 
al., 2005) (1/250 dilution in blocking buffer), which detects a linear epitope on the N-domain 
of sACE. This was followed by a 1 hour incubation in anti-rat antibody (1/2000 dilution in 
blocking buffer). The membrane was then washed with blocking buffer three times for 5 




Immun-Star™ WesternC™ Chemiluminescent Kit (BioRad, (Hercules, CA, USA)) as per 
manufacturer’s instructions and visualized on a G:Box iChemi™ chemiluminescence imager 
(Syngene, Cambridge, UK) for quantification using ImageJ software 
(http://rsbweb.nih.gov/ij). The percentage cleavage was calculated as a function of the 
percentage of full-length sACE detected, by determining the ratio of full-length sACE 
remaining to the individual domain in the entire mixed population sACE isoforms present on 




3.3 RESULTS  
In order to understand the effect of glycosylation on the cleavage of the inter-domain linker 
region of sACE, a panel of MG-sACE mutants with varying N-glycan site occupancy proximal 




Figure 3.2: Diagrammatic representation of MG-sACE mutants showing respective N-glycan site occupancy. 
Glycosylation sites are numbered starting from the N-domain. Glycosylation sites proximal the inter-domain linker region are 





These were transiently expressed in CHO cells, assayed for enzymatic activity, concentrated 
and Western blotted as previously described (see section 3.2). Protection from inter-domain 
linker proteolysis was first investigated by reintroducing the N-glycan at site 6 (N131). When 
comparing sACE3,8,9/11,13 and sACE3,6,8,9/11,13, it was noted that reintroduction of site 
6 resulted in a small, but not significant, reduction in the cleavage (Figure 3.3).  
 
Interestingly, addition of site 2 (N25) to sACE3,8,9/11,13 resulted in a 2-fold increase in the 
cleavage, which was significantly blunted by the addition of site 6 (Figure 3.3). Furthermore, 
sACE2,3,6,8,9/11,13’s level of cleavage was not significantly different to that of WT sACE 
(Figure 3.3). This suggests that site 6 may be important in preventing, or at least limiting 
inter-domain linker proteolysis. Additionally, site 2 appears to increase MG-sACE’s 
susceptibility to proteolysis, possibly by inducing a conformational change that exposes the 
linker region making it more susceptible to proteolysis (Figure 3.7). Substitution of site 11 
(N648) with 12 (N666) revealed a striking result as there was a significant increase in the 
cleavage of sACE3,8,9/12,13 when compared to both WT-sACE and sACE3,8,9/11,13 
(Figure 3.4).  
Figure 3.3: Percentage cleavage graph of MG-sACE mutants with and without glycosylation 
site 6 (N131) intact. A) Bar graph indicating percentage cleavage values of the respective MG-sACE 
mutants from triplicate or more experiments. The percentage cleavage was calculated as a function of 
the percentage of full-length sACE detected. B) Representative Western blots for each MG-sACE 
mutant. ****P ≤ 0.0001, ns = Not significant. Molecular weight marker – PageRuler™ Plus Prestained 
Protein Ladder. Error bars indicate mean ±SD. 






This was unexpected as site 12 is proximal to the inter-domain linker region. Interestingly, 
when site 2 was reintroduced in the presence of site 12 (N666), the cleavage levels were 
reduced dramatically and cleavage was not significantly different to WT-sACE (Figure 3.4). 
This trend between sACE2,3,8,9/11,13 and sACE2,3,8,9/,12,13 is similar to that noticed with 
the reintroduction of site 2 and 6 in a single mutant (Figure 3.3), suggesting that site 12 may 
be playing a role in limiting cleavage but requires the presence of site 2 to cause a 
conformational change or steric hindrance that affects cleavage. When both site 6 and 12 





Figure 3.4: Percentage cleavage graph of MG-sACE mutants with and without glycosylation 
site 12 (N666) intact. A) Bar graph indicating percentage cleavage values of the respective MG-
sACE mutants from triplicate or more experiments. The percentage cleavage was calculated as a 
function of the percentage of full-length sACE detected. B) Representative Western blots for each 
MG-sACE mutant. ****P ≤ 0.0001, ns = Not significant. Molecular weight marker – PageRuler™ Plus 





With the mutant sACE2,3,6,8,9/12,13, the detrimental effect of site 2 is again blunted by the 
presence of both site 6 and 12. The most striking result is noticed with sACE3,6,9/12,13 
which is the least susceptible to proteolysis (Figure 3.5). This suggests that glycosylation 
sites 3, 6, 9, 12 and 13 are crucial for protecting against proteolysis, although the cleavage is 
still significantly higher than that of WT-sACE (Figure 3.5). Furthermore, the presence of a 
disulphide bridge through the H600C substitution did not have a significant effect on 
reducing proteolysis (Figure 3.5).  WT domain substitutions in MG-sACE revealed that the 
presence of a fully-glycosylated N-domain resulted in a 10-fold increase in the percentage 
cleavage when compared to WT-sACE. In contrast, the presence of a fully-glycosylated C-
domain caused an increase in the cleavage when compared to WT-sACE that was not 
significant (Figure 3.6). This suggests that C-domain glycans are more important in 
protecting the inter-domain linker from proteolysis. 
Figure 3.5: Percentage cleavage graph of MG-sACE mutants with a combination of 
glycosylation sites 6 (N131) and 12 (N666) intact and sACE3,6,9/H600C/12,13. A) Bar graph 
indicating percentage cleavage values of the respective MG-sACE mutants from triplicate or more 
experiments. The percentage cleavage was calculated as a function of the percentage of full-length 
sACE detected. B) Representative Western blots for each MG-sACE mutant. **P ≤ 0.01, ****P ≤ 
0.0001, ns = Not significant. Molecular weight marker – PageRuler™ Plus Prestained Protein Ladder. 
Error bars indicate mean ±SD. 






This study investigates the effect of N-glycan site occupancy on the proteolysis of the ACE 
inter-domain linker. The first MG-sACE that was previously generated in our research group 
had three N-glycans proximal to the inter-domain linker (site 8 (N416), 9 (N480) and 13 
(N685)) (Figure 3.1). However, this site occupancy did not prevent inter-domain linker 
proteolysis. Therefore, two additional sites (6 (N131) and 12 (N666)) were reintroduced. A 
striking observation was made upon the reintroduction site 2. It resulted in a significant 
increase in linker proteolysis (Figures 3.3 and 3.4). It is unclear why the reintroduction of site 
2 has this detrimental effect site 2 is located on the lid region of the N-domain (see section 
1.1.2), which is a substantial distance from inter-domain linker region (approximately 60 Å). 
However, differences in N-glycan site occupancy in the lid region have been shown to result 
in local conformational changes within the ACE protein structure, evidenced by reduced 
binding of monoclonal antibodies raised to the epitope in this region of WT-sACE (Taasoli et 
al., 2008). Additionally,  site 2 is known to be important in the expression and thermal 
Figure 3.6: Percentage cleavage graph of domain substitution MG-sACE mutants. A) Bar graph 
indicating percentage cleavage values of the respective MG-sACE mutants from triplicate or more 
experiments. The percentage cleavage was calculated as a function of the percentage of full-length 
sACE detected. B) Representative western blots for each MG-sACE mutant. ***P ≤ 0.001, ns = Not 
significant. Molecular weight marker – PageRuler™ Plus Prestained Protein Ladder. Error bars 




stability of the N-domain (Anthony, 2011), therefore it is possible that it may have different 
functions within sACE. Furthermore, glycosylation has been implicated in inter-domain 
interactions such as homodimerization of ACE (Corradi et al., 2006; Gordon, 2011). Before 
evaluating these data, it is important to note that both the N-glycans and the inter-domain 
linker region display a high degree of flexibility. Therefore, in vitro, MG-sACE may assume 
different conformations depending on these two factors. The presence of some N-glycans 
may favour a conformation that rarely allows access to the linker region by the protease 
responsible for the cleavage, while other N-glycans may favour the opposite. Thus, it is 
possible that N25 at site 2 may induce a conformational change which renders the inter-
domain linker region more susceptible to proteolytic attack (Figure 3.7).  
Figure 3.7: Proposed mechanism of increased susceptibility to proteolysis in 
the presence of glycosylation site 2 in sACE2,3,8,9/11,13. Site 2 may induce a 
conformational change, leaving the inter-domain linker region susceptible to 
proteolytic attack. Glycosylation sites are numbered starting from the N-domain. Sites 
proximal the inter-domain linker region are indicated by grey circles. Proteolytic 






Interestingly, reintroduction of site 6 abolished this increase in susceptibility to proteolysis 
induced by site 2 and this might be due to the following;  
1) N131 might be reversing the N25 induced conformational change in MG-sACE (Figure 3.8 
A), therefore making the inter-domain linker region less susceptible to proteolysis; or 2) The 
presence of a sugar at site 6 may be physically shielding the inter-domain linker region from 
proteolytic attack, even in the glycan 2-induced conformation (Figure 3.8 B). The protective 
effect of site 6 is observed with every MG-sACE mutant in which it is intact, suggesting that 
site 6 is crucial for protecting against inter-domain linker proteolysis.  
 
Replacing a glycan at site 11 with one at site 12 (sACE3,8,9/12,13) had a similar effect to 
the introduction of a glycan at site 2 (Figure 3.4), which was unexpected as site 12 is in close 
proximity to the inter-domain linker region. Previously, N-glycans in the lid subdomain of the 
C-domain (site 11 (N648) and site 12 (N666)) have been proposed to be involved in inter-
domain interactions (Corradi et al., 2006).  
Figure 3.8: Proposed mechanisms of site 6 protection from inter-domain linker 
proteolysis in the presence of glycosylation site 2 using sACE2,3,8,9/11,13, and 
sACE2,3,6,8,9/11,13 as models. A) Site 6 may reverse the site 2 induced conformational 
change, resulting in a conformation of sACE which limits access of the responsible 
protease to the inter-domain linker region. B) Site 6 may physically prevent access of the 
responsible protease to the inter-domain linker region, even in the site 2 induced 
conformation. The complex sugar represents the possible type of glycan attachment to 
N131 at site 6. Glycosylation sites are numbered starting from the N-domain. Sites 
proximal the inter-domain linker region are indicated by grey circles. Proteolytic enzyme is 







Thus, a glycan at site 12 may be interacting with the nearest glycan (N685) at site 13, 
limiting its flexibility and exposing the last few residues of the linker region (see section 
1.1.2) which are the most flexible, and thus more likely to undergo proteolysis.  Interestingly, 
reintroduction of the detrimental site 2 resulted in a striking decrease in the linker proteolysis, 
similar to that seen with WT-sACE (Figure 3.4). This unexpected observation may be 
explained by the fact that a glycan at N666 (site 12) is thought to be involved in inter-domain 
interactions. Therefore, a strong interaction between it and a glycan at N131 (site 6) may be 
occurring, and thus physically shielding the linker region from proteolysis. Alternatively, the 
presence of both N131 and N666 may favour a more stable conformation of sACE which is 
less susceptible to proteolytic attack. Here, an interesting dynamic is observed in the 
presence of two glycans that have synergistic properties when both are present, but have 
detrimental effects when either is absent. This is reminiscent the redundant nature of N-
glycans, where the importance of one may only be noticed when the other is absent/present.  
However, additional work needs to be done to verify the proposed effect of the possible 
interaction between glycans at sites 6 and 12. 
 
A clear synergistic effect is noticed when glycosylation sites 6 and 12 are present in MG-
sACE (Figure 3.5). Interestingly, when only sites 3, 6, 9, 12 and 13 are present, the cleavage 
is dramatically reduced. This suggests that site 8 may not be involved in protecting the linker 
from proteolysis, albeit a glycan that is in close proximity to the linker region. This 
observation paves the way for identifying the least possible intact glycosylation sites required 
for a stable MG-sACE. Stabilization of the linker region through the H600C substitution made 
no significant difference, suggesting that limiting flexibility by the introduction of an additional 
disulphide (Cys474 – Cys600) in the linker does not confer protection from proteolysis 
(Figure 3.5). A construct with a minimally glycosylated N-domain fused to a wild-type C-
domain (sACE3,6,9/WTCdom) revealed similar linker cleavage to that of wild-type sACE. In 




(sACEWTNdom/12,13) resulted in an approximate 10-fold increase in proteolysis (Figure 
3.6). This suggests that N-glycans on the C-domain are more important in protecting from 
inter-domain linker proteolysis. As mentioned previously, the stability of sACE is affected by 
both temperature (thermal stability (see Chapter 4)) and proteolysis. It is well known that the 
N-domain is responsible for most of sACEs thermal stability through extensive N-
glycosylation (Anthony, 2011; O'Neill et al., 2008; Voronov et al., 2002). Thus, it is likely that 
the C-domain may be important in conferring stability, evidenced by its ability to limit inter-




Chapter 4: The effect of glycosylation on the expression 
and stability of sACE 
4.1 INTRODUCTION  
sACE is a membrane-bound protein that is exported to the cell surface in its mature form 
and is also shed from the cell surface (Cannon et al., 2007; Danilov et al., 2011; Friborg et 
al., 2002; Kost et al., 2003; Taastrom et al., 2004; Woodman et al., 2005). Although 
truncated soluble constructs of sACE have been engineered, the membrane-bound form is 
also cleaved and released into the medium as a soluble form. Furthermore, individual 
domains of cleaved membrane-bound MG-sACE mutants are also found in culture medium. 
This prompts the following questions: 1) does inter-domain linker proteolysis occur 
intracellularly or extracellularly? and 2) does it occur during synthesis, post-translationally? 
Thus, determining the location of linker proteolysis will aid in understanding the process of 
proteolysis as well as serve as a stepping stone towards identifying the protease(s) 
responsible.  
 
It is well known that protein glycosylation affects the expression and thermal stability of 
sACE and its individual domain isoforms (Anthony et al., 2010; O'Neill et al., 2008; Voronov 
et al., 2002). Previous work has determined that two N-terminal glycosylation sites are 
required for the expression of functional C-domain (Gordon et al., 2003), while three C-
terminal or two C- and one N-terminal glycosylation sites are required for the N-domain 
(Anthony et al., 2010). An MG-sACE protein (sACE3,8,9/11,13) comprised of these hypo-
glycosylated domains suggests that the same glycosylation sites are sufficient for the 
expression of sACE. However, the effect of additional glycosylation sites on the expression 
of MG-sACE has not been investigated. As previously mentioned, glycosylation site 2 is 
important in both the expression and thermal stability of the N-domain (Anthony et al., 2010), 




study. Furthermore, available MG-sACE mutants were assessed for differences in 
expression and stability profiles (Figure 4.1), with the exception of sACE3,6,8,9/11,13 due to 
its oligosaccharide site occupancy similarity to sACE3,6,8,9/12,13. Expression of MG-sACE 
has proven to be problematic as some mutants are expressed at levels which are insufficient 
for downstream purification. Hence, only a few of the MG-sACE mutants were successfully 
expressed and purified. These were used to investigate the effect of glycosylation on the 
thermal stability. 
Figure 4.1: Diagrammatic representation of MG-sACE mutants assessed for differences in expression and stability 
profiles. Black boxes indicate intact glycosylation sites and white boxes indicate sites that are not glycosylated. Numbers 
indicate glycosylation site positions. 
*Mutants generated by C.S. Anthony (2011). 
‡






1) To determine the cellular localization of the inter-domain linker proteolysis. 
2) To investigate the effect of N-glycosylation on the expression of sACE. 
3) To investigate the effect of N-glycosylation on the thermal stability of sACE. 
4.2 EXPERIMENTAL METHODS 
4.2.1 Transfection and expression 
MG-sACE mutants were initially transiently transfected and mutants displaying high 
enzymatic activity from these experiments were stably transfected for selection and 
purification (Table 4.1). 
 
MG-sACE Transient Stable 
sACEWTNdom/12,13     × 
sACE3,6,9/WTCdom     
sACE2,3,6,8,9/11,13      × 
sACE2,3,6,8,9/12,13      × 
sACE2,3,8,9/11,13      × 
sACE2,3,8,9/12,13      × 
sACE3,6,8,9/12,13     
sACE3,8,9/11,13     
sACE3,8,9/12,13      × 
sACE3,6,9/12,13      × 
 
4.2.1.1 Transient transfection of MG-sACE in CHO cells 
All transient transfections were carried out as described in section 3.2.1. For determining the 
cellular localization of proteolysis, complete growth medium was replaced with serum-free 
medium (Gibco Opti-MEM, Invitrogen, USA) 24 hours post analysis.  
4.2.1.2 Stable transfection, selection and expression of high expressing 
recombinant MG-sACE in CHO cells 
High expressing recombinant MG-sACE constructs were stably transfected into CHO cells 
as follows. Cells were seeded into 10 cm3 plates in complete growth medium (10% FCS, 
43% DMEM, 43% F-12 HAMS, 20 mM HEPES pH 7.5) at 37°C with 5% CO2, until 50% 





confluency was reached. These were then transfected with template DNA inserted in 
pCDNA3.1(+) using the CaPO4 method (ProFection® Mammalian Transfection Systems kit - 
Promega, WI, USA) as per manufacturer’s instructions. Cells were incubated with complete 
growth medium overnight, which was then replaced with selective medium containing 0.8 
mg/ml of Geneticin (G418, Sigma, MO, USA). Geneticin resistant colonies were picked from 
the mixed culture using sterile toothpicks and seeded in duplicate into 24-well plates. For 
cells expressing transmembrane constructs, one well was lysed using lysis buffer (1% (v/v) 
Triton X-100, 50 mM HEPES, 500 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF)) 
and assayed for enzymatic activity. Cells expressing soluble constructs were incubated in 
2% FCS for 24 hours and assayed for activity. Clones having high activity were lifted using 
trypsin-EDTA (0.5% (w/v) Trypsin, 0.5 mM EDTA, PBS pH 7.4). And grown further for stocks 
(Appendix A6). This was repeated until cells were transferred into two T75 tissue culture 
flasks. Cells expressing transmembrane constructs were sorted. FACS was carried out at 
the Institute of Infectious Disease and Molecular Medicine (IDM, University Of Cape Town). 
Cells in a T75 were washed three times with 1x PBS and lifted with trypsin-EDTA, then 
resuspended in 1 ml 1x PBS. Cells were labelled with 10 µg/ml of primary monoclonal 
antibody 1D8 raised to an epitope on the central part of the C-domain (Balyasnikova et al., 
2005; Nikolaeva et al., 2006), for 30 minutes at room temperature. These were centrifuged 
and washed with 1x PBS three times. Cells were then incubated with 5 µl Alexa Fluor® 488 
Goat Anti-Mouse IgG (H+L) antibody (Sigma, MO, USA) for 30 minutes on ice in the dark. 
Cells were washed as mentioned above and resuspended in 1 ml 10% FCS and transferred 
to a falcon tube. Sorted cells were added to a T25 culture flask with 10% FCS containing 1% 
(v/v) Penicillin Streptomycin and allowed to grow to confluency. Cells were then lifted and 
transferred into multiple T175 culture flasks. These were lysed with lysis buffer and lysates 
were collected in sterile 50 ml tubes. Cell lysates were centrifuged at 4000xg at 4˚C for 15 
minutes. The resultant supernatants were collected in sterile 50 ml tubes and stored at -20˚C 




T175 flasks and incubated with 2% FCS at standard conditions. Medium was harvested after 
48 to 72 hours into sterile 50 ml tubes and stored at -20˚C until used. 
4.2.2 Sample preparation for using lisinopril affinity resin 
Samples for determining the cellular localization of inter-domain linker proteolysis were 
prepared as described in section 3.2.3.  
4.2.3 Western blotting and densitometry 
Western blotting and densitometry was carried out as described in section 3.2.4. There was 
a variation in the primary antibody used to determine the cellular localization of proteolysis. 
Here, an antibody cocktail of two monoclonal anti-ACE antibodies (4G6 and 1D8 
(Balyasnikova et al., 2003; Balyasnikova et al., 2005; Nikolaeva et al., 2006)) was used to 
detect both the N- and the C-domain.  
4.2.4 Enzymatic activity determination via Z-Phe-His-Leu (Z-FHL) fluorimetric 
assay 
Enzymatic activity was determined as described in section 3.2.2. 
4.2.5 Purification of MG-sACE proteins 
Expressed proteins were purified using lisinopril-sepharose affinity chromatography (Ehlers 
et al., 1991). Medium/lysate harvests were allowed to flow through the column at a speed of 
1.0 ml/min. Once the medium/lysate was loaded onto the column, wash buffer was allowed 
to flow through at a speed of 0.25 ml/min overnight to wash off unbound protein. Bound 
protein was pH eluted with degassed 50 mM borate at pH 9.5 and 2 ml fractions were 
collected. Fractions showing ACE activity were pooled and dialysed in 2x 2 litres 50 mM 
HEPES with 0.1 mM PMSF at 4˚C. Protein was concentrated to approximately 500 µl using 
30000 kDa Amicon® Ultra-4 centrifugal filter units (Millipore, Cork, Ireland). The optical 
density, at a wavelength 280 nm (OD280), was read using NanoDrop™ 1000 
spectrophotometer to determine the concentration of the final protein using a calculated 




4.2.6 Protein Purity Determination via SDS-PAGE 
Protein purity was assessed using a standard SDS-PAGE protocol (Appendix A4). Proteins 
were then stained with Coomassie (0.2% (w/v) Coomassie Blue, 7% (v/v) glacial acetic acid, 
50% (v/v) ethanol) overnight and destained in destain solution (7% (v/v) glacial acetic acid, 
25% (v/v) ethanol) for visualization 
4.2.7 Determination of kinetic constants for Z-FHL hydrolysis 
Kinetic parameters for Z-FHL (Bachem, Budendorf, Switzerland) hydrolysis were determined 
using the abovementioned fluorimetric assay. Initial reaction rates were calculated using Z-
FHL concentration range of 0.00 to 2.5 mM. Assays were done at least three times in 
triplicate. Data was fitted in GraphPad Prism (GraphPad Software Inc., USA) and Michaelis-
Menten constants (Km, Vmax, kcat and kcat/Km) were calculated accordingly. Kinetic values 
were normalized according to the specific activities of each protein.  
4.2.8 Thermal denaturation assay 
Purified MG-ACE proteins were incubated at 55°C for up to 90 min in 50 mM HEPES, pH 







4.3.1 Determining cellular localization of inter-domain linker proteolysis 
To determine the cellular location of inter-domain linker proteolysis, cell lysate and medium 
were harvested from cells expressing sACE3,6,8,9/12,13 and analysed using Western 
blotting (Figure 4.2). Full-length MG-sACE corresponding to the band at 160 kDa was 
observed in both the cell lysate and the medium. Similarly, the N-domain corresponding to 
the band at 90 kDa was also found in both lysate and medium. In contrast, the C-domain 
that ran with a higher mobility than the N-domain due to its lower content of 












Figure 4.2: Western blot of sACE3,6,8,9/12,13 medium and lysate samples with a
cocktail of monoclonal antibodies directed towards the N-domain (4G6) and the C-
domain (1D8). Full length mg-sACE, N-domain and C-domain are indicated with black
arrows. MW - PageRuler™ Plus Prestained Protein Ladder.
i re 4.2: ester  l t f s 3,6,8,9/12,13 e i  a  lysate sa les it  a 
cocktail of onoclonal antibodies directed to ards the N-do ain (4 6) and the C-
domain (1D8). Full-length MG-sACE, N-domain and C-domain are indicated with black 
arrows. MW - PageRuler™ Plus Prestained Protein Ladder. 




Figure 4.3: Graph indicating total active protein per transient transfection. The activity/pixel density ratio was determined 
using western blotting, densitometry and the activity in mU/ml of each sample. Transfections were done in duplicate. Error bars 
indicate mean ±SD.  
4.3.2 The effect of glycosylation on the expression of unpurified MG-sACE 
proteins 
To assess the effect of glycosylation on the expression of MG-sACE, constructs were 
transiently expressed and assayed for enzymatic activity as described in sections 4.2.1.1 
and 4.2.4. Western blotting and densitometry were then used to obtain the full-length MG-
sACE pixel density (PD) (total peak area) of the bands from each blot. This was then 
normalized by calculating ACE activity over PD ratio (mU/ml/PD). This value gives an 
indication of the total active protein per transient transfection, similar to the specific activity. 
This was done due to the fact that the specific activities of some MG-sACE could not be 
determined as expression levels were too low for protein purification and characterization. 
As seen in Figure 4.3, MG-sACE variants with only five intact glycosylation sites (sites 3 
(N45), 6 (N131) or 8 (N416), 9 (N480), 12 (N666) and 13 (N689)) displayed an 





Furthermore, addition of site 2 (N25) did not have a notable effect on the abovementioned 
variants, suggesting that this site is not important in the expression of sACE. Interestingly, 
MG-sACE variants that have both sites 6 and 2 intact have an overall higher activity/PD 
ratio, suggesting that these sites, in combination, are important in maintaining a high 
expression profile. When site 12 is substituted with site 11 (N648), the activity/PD ratio is 
increased slightly (Figure 4.3). Surprisingly, an MG-sACE with a fully glycosylated N-domain 
that has 12 potential glycosylation sites has a slightly lower activity/PD ratio compared to 
those with six intact sites (Figure 4.3), highlighting the fact that there is some redundancy of 
the N-glycosylation sites in sACE. 
4.3.3 The effect of glycosylation on the expression of purified MG-sACE 
proteins  
Relatively high expressing MG-sACE variants were purified as described in section 4.2.5. 
Purification yields were 381 mg/L for sACE3,8,9/,11,13; 122 mg/L for sACE3,6,8,9/12,13; 
and 381 mg/L for sACE3,6,9/WTCdom. To determine the effect of glycosylation on ACE 
expression, the specific activity was calculated promptly after purification and the degree of 
purity was assessed by SDS-PAGE as described in section 4.2.6. The specific activities of 
sACE3,8,9/11,13 and sACE3,6,9/WTCdom were found to be almost 6-fold lower than that of 
WT-sACE (Figure 4.4 A). Interestingly, a sharp increase in the specific activity was noticed 
with sACE3,6,8,9/12,13, further highlighting the importance of site 6 (Figure 4.4 A) (see 
section 4.3.2). Furthermore, minor changes in the electrophoretic mobility of the hypo-
glycosylated constructs sACE3,8,9/11,13 and sACE3,6,8,9/12,13 were noticed (Figure 4.4 
B), correlating with the decrease in the number of intact glycosylation site and thus, in the N-




Purified MG-sACE samples are comprised of a population of three sACE isoforms (full-
length sACE and the proteolytically cleaved N- and C-domains). The individual domains are 
known to be active which may have an effect on the enzymatic activity readings. However, 
the amount of the individual domains in each sample is unlikely to have a significant effect 
on MG-sACE functionality. To address this issue, MG-sACE mutants were kinetically 
characterized and compared with WT-sACE to ensure that the functional integrity of the 
minimally glycosylated constructs had not been compromised. Kinetic constants for 
sACE3,8,9/11,13 have previously been determined and were found to be similar to those of 
WT-sACE (Anthony, 2011). Michaelis-Menten curves for the hydrolysis of Z-FHL were 
plotted for each purified mutant and the Km values for WT-sACE, sACE3,6,8,9/12,13 and 
sACE3,6,9/WTCdom were found to be very similar at 0.33 mM, 0.32 mM and 0.31 mM 
respectively. Similarly the Kcat values and the catalytic efficiencies (Kcat/Km) were found to be 
Figure 4.4: Expression of WT-sACE and MG-sACE mutants. A) Calculated specific activities of WT-sACE, 
sACE3,8,9/11,13, sACE3,6,8,9/12,13 and sACE3,6,9/WTCdom are shown, B) Representative SDS=PAGE gels of each sACE 





comparable (Figure 4.5). These data suggest that MG-sACE is functioning with a similar 
efficiency to WT-sACE. 
 
4.3.4 The effect of glycosylation on the thermal stability of purified MG-sACE 
proteins  
For investigating the effect of N-glycan site occupancy on the thermal stability of purified 
MG-sACE mutants, thermal denaturation experiments were carried out. This method is 
based on the transformation of a well-defined, folded structure of a protein formed under 
physiological conditions to an unfolded state under conditions of increased temperature. The 
residual enzymatic activity of each mutant is determined at 55ºC over 90 minutes, giving an 
indication of how much active protein remains and thus, how thermally stable each protein 
is. The thermal stability was then determined and plotted as shown in Figures 4.6 and 4.7. 
As previously mentioned, the N-domain has been shown to be the major contributing factor 
towards the thermal stability of sACE. This is evident in Figure 4.6 where the WTNdom 
retains 60% activity after 15 minutes at 55°C followed by WT-sACE and 
sACE3,6,9/WTNdom at approximately 15%, sACE3,6,8,9/12,13 at 10%, WTCdom at 6% 
and sACE3,8,9/11,13 at only 2% remaining activity.  













Figure 4.6: The effect of glycosylation on sACE thermal stability. Thermal denaturation assays were done as described in 




The most notable difference between the percentage remaining activities is seen at after 2.5 
minutes (Figure 4.7), where WTNdom retains a remarkable 84%, followed by WT-sACE 
retaining 47%, sACE3,6,9/WTCdom retaining 28%, WTCdom and sACE3,6,8,9/12,13 
retaining approximately 20% and sACE3,8,9/11,13 only retaining 9%. After 90 minutes WT-





Figure 4.7: The effect of glycosylation on sACE thermal stability. Thermal denaturation assays were done as described in 




This investigation was aimed at determining the cellular localization of the inter-domain 
proteolytic event and the effect of N-glycan site occupancy on the expression and thermal 
stability of somatic ACE. Interestingly, only N-domain and full-length MG-sACE were found 
in the cell lysate and medium samples (Figure 4.2), while the C-domain was only found in 
the lysate, suggesting that proteolysis occurs in the intracellular milieu. As mentioned in 
Chapter 1, sACE has a signal peptide that is required to initiate exportation to the cell 
surface. This signal peptide is located at the N-terminus of sACE, i.e. on the N-domain. 
Therefore, after inter-domain linker proteolysis, there are two possible fates of MG-sACE 





Figure 4.8: Diagrammatic representation of the fates of MG-sACE intra- and extracellular.    
 
Firstly, the MG-sACE population that does not undergo proteolysis is successfully exported 
to the cell surface where it undergoes ectodomain shedding. Secondly, the population of 
MG-sACE that undergoes linker proteolysis results in some N-domain being exported to the 
cell surface while another batch is retained and degraded intracellularly. Due to the fact that 
the N-domain lacks the stalk and transmembrane region of sACE, it is not anchored to the 
cell membrane and is secreted into the medium (Figure 4.8). Furthermore, the C-domain, is 
retained within the cell as it lacks the signal peptide required for exportation to the cell 




suggesting that it may be degraded within the cell to avoid accumulation of an obsolete 
intracellular C-domain. 
As previously mentioned, N-glycans play a crucial role during the folding and processing of 
sACE. A decrease in expression is noticed when N-glycosylation sites are removed. 
Therefore, expressing MG-sACE mutants at sufficient levels for purification is difficult. Thus, 
a qualitative study was done to explore the effect of glycosylation on expression for MG-
sACE mutants that could not be expressed in sufficient quantities for purification. It was 
found that MG-sACE mutants with only five glycosylation sites intact had a very low 
expression profile, while those with an additional site 6 (N131) fared better (Figure 4.3), 
suggesting that this site might be important during the in vitro processing of sACE. 
Furthermore, site 2, has been shown to be important in maintaining the expression profile of 
the individual N-domain (Anthony et al., 2010). However, in contrast to the effect of a glycan 
at site 6, site 2 did not seem to have a significant effect on the expression of MG-sACE. It is 
important to note that the effect of each glycosylation site on sACE has not been fully 
investigated and the rationale behind the design of MG-sACE mutants is based on what is 
available in literature about the individual truncated domains. Therefore, sites that may be 
important in the expression of the individual domains may not necessarily be as important in 
sACE. This is reminiscent of the differences in the glycosylation requirements for each 
domain where the C-domain relies on N-terminal glycans (Gordon et al., 2003), while with 
the N-domain three C-terminal glycans were necessary and sufficient for expression 
(Anthony et al., 2010). Interestingly, a fully glycosylated N-domain within MG-sACE did not 
have a significantly different effect on expression compared to a MG N-domain (Figure 4.3). 
Thus, it is possible that for sACE, a unique combination of glycosylation sites on both 
domains may be required for appropriate processing of sACE. This may be due to 
differences in the secondary and tertiary structures of sACE which may require glycans 
located at key sites in order to facilitate multiple protein folding cycles (see section 1.2.3). 




Mutants that were expressed at levels sufficient for expression confirmed three points: 
Firstly, MG-sACE mutants with five glycosylation sites intact have the lowest expression 
profile (Figures 4.3 and 4.4 A). This may be because a combination of glycosylation sites 3, 
6 or 8, 9, 11 or 12 and 13 does not allow for optimal in vitro processing or additional site(s) 
may be required. This is in contrast to the tACE (C-domain), where only one or two glycans 
were necessary and sufficient for correct processing and enzymatic activity of this isoform 
(Gordon et al., 2003). 
Secondly, a fully glycosylated domain (C-domain) within MG-sACE does not have a marked 
effect on the expression of sACE (Figures 4.3 and 4.4 A). Again, this suggests that a 
particular combination of glycans on both domains is required for optimal processing. 
Thirdly, site 6 has the most notable effect on the expression of MG-sACE (Figures 4.3 and 
4.4 A). Therefore, in addition to its role in preventing inter-domain linker proteolysis, this site 
may also be crucial for the expression of sACE. 
 
There exist several quantitative methods for investigating the degree of protein thermal 
stability, including differential scanning calorimetry and circular dichroism spectroscopy. 
However, these methods require a high concentration of protein, which poses a problem for 
MG-sACE mutants which have low protein purification yields. Therefore, thermal 
denaturation, a simpler and timeous semi-quantitative method that requires minimal protein 
amounts was used. ACE thermal denaturation assays rely on the functional integrity of 
proteins under investigation. As previously mentioned, purified MG-sACE samples 
essentially have three different populations of sACE isoforms, therefore caution has to be 
taken when analysing enzymatic activity data. To address this, kinetic analyses were carried 
out to determine whether each minimally glycosylated mutant has a similar catalytic 
efficiency to WT-sACE. Indeed, kinetic constants of the purified mutant proteins were 




sACE is mostly responsible for the enzymatic activity from each sample, even in the 
presence of traces of the individual domains.  
 
Investigating the effect of glycosylation on the thermal stability revealed that the most 
thermally stable MG-sACE mutant is sACE3,6,9/WTCdom (Figures 4.6 and 4.7), which is 
expected as the bulk of sACE’s thermal stability is mediated by N-glycans and this MG-
sACE mutant has the highest site occupancy (Anthony et al., 2010; O'Neill et al., 2008). 
Interestingly, reintroduction of 6 site along with a site 11 to 12 substitution was able to 
rescue the stability of the least stable mutant (sACE3,8,9/11,13) from 9% to 20% (similar to 
the WT C-domain value) after 2.5 minutes (Figure 4.7), further highlighting the importance of 
site 6. These data suggest that a complex combination of glycosylation sites within sACE is 
important in maintaining adequate expression and thermal stability. However, this effect 
needs to be investigated more quantitatively to corroborate these findings. 
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Conclusions and future work 
We determined the minimum glycosylation requirements for a stable MG-sACE to be 
combinations of glycans attached to residues N25, N45, N131, N416, N480, N648 and N685 
(sACE2,3,6,8,9/11,13) or N25, N45, N416, N480, N666 and N685 (sACE2,3,8,9/12,13). 
Interestingly, addition of N25 (site 2) to sACE3,8,9/11,13 resulted in a sharp increase in 
inter-domain linker proteolysis, likely due to a conformational change caused by this site 
occupation. This effect was blunted by the presence of N131 (site 6) and/or N666 (site 12). 
Also, N416 at site 8 was found to have no protective effect in terms of inter-domain linker 
proteolysis, evidenced by protection conferred by N45, N131, N480, N666 and N685 in 
sACE3,6,9/12,13 in comparison to sACE3,8,9/12,13. Limiting inter-domain linker flexibility by 
disulphide bridge formation had no notable effect on protection from proteolysis. 
Furthermore, we identified C-domain N-glycans as being crucial in maintaining adequate 
protection from proteolysis. Although MG-sACE constructs that are the least susceptible to 
linker proteolysis have been identified, these are still relatively highly glycosylated, which is 
problematic for X-ray crystallography. Thus, steps need to be taken to inhibit linker 
proteolysis. This could be done by identifying the linker cleavage site(s). Identified residue(s) 
at the cleavage site(s) could then be converted to more rigid amino acids such as proline 
which might be less susceptible to linker proteolysis. Initial attempts to do this using limited 
proteolysis and mass spectrometry were unsuccessful due to the nature of the peptides 
generated. Here, limited proteolysis using trypsin was conducted, however, predicted inter-
domain linker peptide fragment masses could not be identified.  It would thus be beneficial to 
consider different digest agents such as Glu-C or Lys-C. Additionally, another technique 
such as N-terminal sequencing could be employed.  
 
Inter-domain linker proteolysis was found to occur intracellularly. An interesting occurrence 
was noticed in this study. Mature MG-sACE was successfully exported to the cell surface, 
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while some N-domain was secreted to the extracellular milieu and both the N- and C-domain 
were retained and degraded intracellularly. This limits the range of protease candidates to 
intracellular enzymes, serving as a step closer to identifying the protease(s) responsible for 
the cleavage of the linker in MG-sACE.  
Glycosylation site 6 (N131) was found to be important in protection from proteolysis, high 
expression and thermal stability. In contrast, site 2 (N25), which is known to play a role in 
maintaining a high expression and thermal stability profile of the individual N-domain 
(Anthony et al., 2010), had no notable effect on MG-sACE’s expression and thermal stability. 
Surprisingly, a fully-glycosylated N- or C-domain fused with their minimally glycosylated 
counterparts had no dramatic effect on the expression of MG-sACE. This indicates that a 
unique combination of glycans on both domains is required to maintain adequate expression 
of sACE unlike the tACE isoform which only requires one or two glycans (Gordon et al., 
2003). Due to low expression levels displayed by MG-sACE mutants, expression systems 
with the appropriate glycosylation machinery such as yeast could be better options. Previous 
studies have described the different glycosylation requirements for minimally glycosylated 
sACE and tACE isoforms in yeast (Sadhukhan et al., 1996; Williams et al., 1996) and 
differences in glycosylation requirements for recombinant proteins in mammalian cells 
(Croset et al., 2012). Interestingly, glycoforms which were not sufficiently expressed in 
mammalian cells, were expressed in yeast cells and vice versa, with a certain level of 
overlap. Thus, exploring yeast expression could be beneficial in obtaining MG-sACE at 
sufficient amounts for purification. Wild-type sACE was successfully cloned into two yeast 
expression vectors (data not included in this thesis). These could be used as subcloning 
templates for generating MG-sACE constructs in yeast vectors. 
We determined that MG-sACE proteins were functionally comparable to WT-sACE at 37ºC, 
however, glycosylation had a significant effect on temperature stability. The most thermally 
stable mutant was sACE3,6,9/WTCdom, which is not surprising as it has nine potential 
oligosaccharides, which are known to confer sACE thermal stability (Anthony et al., 2010; 
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O'Neill et al., 2008; Voronov et al., 2002). Additionally, reintroduction of glycosylation site 6 
(N131) and substitution of site 11 (N648) with site 12 (N666) was able to rescue the thermal 
stability of sACE3,8,9/11,13 from 9% to 20% after 2.5 minutes. Additional work needs to be 
done on purified MG-sACE constructs to further investigate the role of N-glycans on the 
thermal stability and expression of sACE. 
Overall, this work resulted in production of a number sACE constructs with varying degrees 
glycan site occupancy. Previous studies have successfully generated individual domain 
mutants of similar N-glycan site occupancy variation, which led to the solution the N- and C-
domain crystal structures (Anthony et al., 2010; Gordon et al., 2003). These newly generated 
sACE glycoforms could be used as tools to further identify key N-glycans which could 
potentially lead to acquiring the high resolution 3D structure of sACE, the importance of 
which cannot be overstated, as this will aid in understanding the complexities of ACE’s 
functionality and involvement in a variety of non-traditional roles mentioned in Chapter 1.  
More importantly, the structure of sACE could drive the design of potent inhibitors with much 





A1) sACE protein sequence and internal sequencing primers 
A set of internal sACE primers were used for DNA sequencing. 
 
Figure A1. Schematic representation of the sACE gene with forward primers indicated above the gene and reverse 
primers indicated below. The nucleotide position of the beginning of the forward primer is indicated. Adapted from Gordon, 
2011. 
 
Figure A2. Amino acid sequence of sACE. Signal peptide targeting the enzyme for secretion is underlined (not 





A2) Expression vectors 








Figure A2: pBSK II KS/SK + plasmid. For bacterial cell 
transformation. 
 




A3) Hippuryl-His-Leu standard curve 
Hippuryl-His-Leu (HL) standards were prepared from a 5.7 mM stock solution in 1x 
phosphate buffer, pH 8.3, at concentrations of 0; 0.037; 0.074; 0.148; 0.296; 0.592 mM. 
 




𝐹𝑈 𝑥 (𝜇𝑙 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒)𝑥 (𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟)
(𝐻𝐿 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑢𝑟𝑣𝑒 𝑠𝑙𝑜𝑝𝑒)𝑥 (𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒)𝑥 (𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑠𝑠𝑎𝑦𝑒𝑑)
 
 
Where FU is the fluorescence intensity. 
  
Figure A4: HL standard curve for enzyme activity calculation, showing correlation between 




A4) SDS-polyacrylamide gel electrophoresis (SDS-PAGE)  
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out as per standard 
laboratory protocols. Here, 20 μl of sample was mixed with 5 μl 5x sample buffer (50% (v/v) 
glycerol, 25% (v/v) β-mercaptoethanol, 15% (w/v) SDS, 0.31 M Tris, 0.25% (w/v) 
bromophenol blue) and denatured at 100˚C for 5 minutes. Denatured samples were 
separated on 10% polyacrylamide gels (0.1% SDS, 375 mM Tris buffer, pH 8.8) and 3% 
stacking (0.1% SDS, 125 mM Tris buffer, pH 6.8) with 0.1% (w/v) ammonium persulphate 
(AMPS) and 10 μl tetramethylethylenediamine (TEMED) in a Tris-glycine tank buffer (pH 
8.3).. Electrophoresis was carried out at 25 mA/gel for 1 hour. 
A5) Z-FHL working solution 
A 20 mM stock solution of Z-FHL was prepared by dissolving 110 mg Z-FHL in 1 mL 0.28 M 
NaOH, and made up to 10 mL with dH2O. The 1 mM Z-FHL working solution was prepared 
by adding 15 ml dH2O to 4 ml 5x phosphate buffer (0.5 M potassium phosphate, pH 8.3, 1.5 
M NaCl) with 20 μl 10 mM ZnSO4, and 1 ml of 20 mM Z-FHL. 
A6) Freezing of CHO cells for storage in liquid nitrogen 
Cells from a confluent T75 were lifted using trypsin-EDTA into a 10 ml blue cap tube which 
was centrifuged for 30 seconds at 4000xg. The supernatant was removed and cells were 
resuspended with 3 ml of ice cold 10% Dimethyl sulfoxide (DMSO) prepared in FCS. Cells 
were kept on ice for 20-30 minutes and aliquoted into six vials. These were promptly 
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